<html><head>
<meta http-equiv="content-type" content="text/html; charset=UTF-8"><link href="https://raw.githubusercontent.com/JohnCiubuc/userstyles/master/dmp.9194f7e7.css" type="text/css"></head><body class="vsc-initialized"><div class="RCL_TemplateMaster RCL_TemplateMaster__three RCL_TemplateMaster__paddingBottom"><div class="RCL_TemplateMaster_cell RCL_TemplateMaster_cellOne"><div class="Topic_wrap"><div class="Topic_body TopicBody"><div class="RCL_ContentBlock"><div class="body"><anid>T922139;T922139.xml;20201105;DataLoaderFramework.EpMarcCitation;3.20.0.0</anid> <title>Pulmonary Edema - Approach to the Patient</title> <ulist collapsible="true" type="RecentUpdates"> <label>Updated 2018 Dec 04 03:08 PM (ET)</label> <inputstring string="2018-12-04T20:08:00Z" type="DateTime" standard="ISO8601"></inputstring> <li class="li">review of noninvasive ventilation in cardiogenic pulmonary edema (Ann Transl Med 2018 Sep) <a class="link internal jump-link" href="#REVIEW-ARTICLES--ANC-1352199889">view update</a></li> <li class="li">review of assessment of pulmonary edema (J Cardiothorac Vasc Anesth 2018 Apr) <a class="link internal jump-link" href="#REVIEW-ARTICLES--ANC-2067545623">view update</a></li> <li class="li">insufficient
 evidence to evaluate efficacy of pharmacological and nonpharmacological
 treatments for altitude illnesses (Cochrane Database Syst Rev 2018 Jun 
30) <a class="link internal jump-link" href="#HIGH-ALTITUDE-PULMONARY-EDEMA--HAPE---ANC-1927338731">view update</a></li>  <p> </p> <anchor name="Top"></anchor> <p>Clinical presentation is variable, and features of cardiogenic and noncardiogenic edema can overlap.</p> <!--SEC NO TITLE--> <p> <ephtml></ephtml></p><div class="TableModal_modalContent" data-auto="table-details"><table class="table" frame="border" rules="all" summary="" id="ID0ELC" cellspacing="0" cellpadding="4" border="1"><colgroup><col style="width:100%"></colgroup><tbody><tr class="row"><td class="entry cellrowborder"><strong>Topic Editor</strong> <a href="#Special-acknowledgements">Constantine Manthous, MD</a></td></tr><tr class="row"><td class="entry cellrowborder"><strong>Deputy Editor</strong> <a href="#Special-acknowledgements">Terence K. Trow, MD, FACP, FCCP</a></td></tr></tbody></table></div> <p></p> <section id="sec-Related-Summaries" collapsible="true" bullettype="arrow"> <h2 id="Related-Summaries">Related Summaries</h2> <anchor name="Related-Summaries"></anchor> <ul class="ul"> <li class="li"> <eplink linkfield="AN" linkkey="T114879">Acute heart failure</eplink> </li> <li class="li"> <eplink linkfield="AN" linkkey="T114099">Heart failure with reduced ejection fraction</eplink> </li> <li class="li"> <eplink linkfield="AN" linkkey="T193266">Heart failure with preserved ejection fraction</eplink> </li> <li class="li"> <eplink linkfield="AN" linkkey="T113803">Acute respiratory distress syndrome (ARDS)</eplink> </li> <li class="li"> <eplink linkfield="AN" linkkey="T921315">Chest x-ray patterns in the differential diagnosis of lung disorders</eplink> </li> <li class="li"> <eplink linkfield="AN" linkkey="T919220">Transfusion-associated lung disorders</eplink> </li> </ul> </section> <section id="sec-General-Information" collapsible="true" bullettype="arrow"> <h2 id="General-Information">General Information</h2> <anchor name="General-Information"></anchor> <section id="sec-Classifications"> <h3 id="Classifications">Classifications</h3> <anchor name="Classifications"></anchor> <ul class="ul"> <li class="li">traditional classification of pulmonary edema<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>)</sups></sc><ul class="ul"><li class="li"> cardiogenic - result of increased pulmonary capillary hydrostatic pressure (often in context of left heart disease) </li><li class="li"> noncardiogenic - occurs due to increased pulmonary capillary endothelial permeability following direct or indirect lung injury </li></ul></li> <li class="li">significant overlap is possible, with patients presenting features of both cardiogenic and noncardiogenic edema (such as in <eplink linkfield="AN" linkkey="T919220">transfusion-related acute lung injury</eplink>, <eplink linkfield="AN" linkkey="T116210">high altitude pulmonary edema</eplink> or <eplink linkfield="AN" linkkey="T922924">neurogenic pulmonary edema</eplink></li> </ul> </section> </section> <section id="sec-Differential-Diagnosis" collapsible="true" bullettype="arrow"> <h2 id="Differential-Diagnosis">Differential Diagnosis</h2> <anchor name="Differential-Diagnosis"></anchor> <section id="sec-Causes-by-edema-type"> <h3 id="Causes-by-edema-type">Causes by edema type</h3> <anchor name="Causes-by-edema-type"></anchor> <section id="sec-Causes-of-cardiogenic-edema"> <h4 id="Causes-of-cardiogenic-edema" level="1"> Causes of cardiogenic edema</h4> <anchor name="Causes-of-cardiogenic-edema"></anchor> <ul class="ul"> <li class="li"> causes of cardiogenic edema include <ul class="ul"><li class="li"><eplink linkfield="AN" linkkey="T115920">mitral stenosis</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T115306">mitral regurgitation</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T114195">aortic stenosis</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T113982">aortic regurgitation</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T114099">heart failure with reduced ejection fraction</eplink>, which can be seen in patients with <ul class="ul"><li class="li"> ischemic cardiomyopathy </li><li class="li">tachyarrhythmia, such as in <eplink linkfield="AN" linkkey="T115288">atrial fibrillation</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T114780">dilated cardiomyopathy</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T115915">peripartum cardiomyopathy</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T901072">takotsubo syndrome</eplink></li></ul></li><li class="li"><eplink linkfield="AN" linkkey="T114748">restrictive cardiomyopathy</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T193266">heart failure with preserved ejection fraction</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T115426">hypertrophic cardiomyopathy</eplink></li><li class="li"> hyperperfusion with blood, blood products, or fluids, as seen in<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>, <a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc><ul class="ul"><li class="li"><eplink linkfield="AN" linkkey="T919220">transfusion-associated circulatory overload (TACO) </eplink></li><li class="li"> volume overload </li><li class="li">patients receiving chronic dialysis (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/29168475?dopt=Abstract" target="%5Fblank">Nat Rev Dis Primers 2017 Nov 23;3():17088</a>)</li></ul></li><li class="li"> high dietary salt load<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li><li class="li"> uncontrolled hypertension<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li><li class="li"><eplink linkfield="AN" linkkey="T115392">myocardial infarction</eplink><sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li><li class="li"><eplink linkfield="AN" linkkey="T114874">pheochromocytoma</eplink><sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li><li class="li"><eplink linkfield="AN" linkkey="T115312">renal artery stenosis</eplink><sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li></ul></li> </ul> </section> <section id="sec-Causes-of-noncardiogenic-edema"> <h4 id="Causes-of-noncardiogenic-edema" level="1"> Causes of noncardiogenic edema</h4> <anchor name="Causes-of-noncardiogenic-edema"></anchor> <ul class="ul"> <li class="li"> causes of noncardiogenic edema include <ul class="ul"><li class="li"><eplink linkfield="AN" linkkey="T113803">acute respiratory distress syndrome (ARDS)</eplink>, such as that seen in <eplink linkfield="AN" linkkey="T919220">transfusion-related acute lung injury (TRALI)</eplink></li><li class="li"> negative-pressure pulmonary edema due to upper airway obstruction, as can be seen in<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3105">3</a>, <a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc><ul class="ul"><li class="li"> postextubation <eplink linkfield="AN" linkkey="T921927">laryngospasm</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T113626">foreign body aspiration</eplink></li><li class="li"> inspissated tracheal secretions </li><li class="li"><eplink linkfield="AN" linkkey="T115733">hiccups</eplink></li><li class="li"> thyroid goiter </li><li class="li"> temporomandibular joint arthroscopy </li><li class="li"> difficult intubation </li><li class="li"> hematoma </li><li class="li"> upper airway tumor </li><li class="li"> oropharyngeal surgery </li><li class="li"> Ludwig angina </li><li class="li"> acromegaly </li><li class="li"> mediastinal tumor </li><li class="li"> severe patient-ventilator asynchrony </li><li class="li"> sleep-disordered breathing </li></ul></li><li class="li"> ascent to elevation &gt; 2,500 meters (8,202 feet) (<eplink linkfield="AN" linkkey="T116210">high altitude pulmonary edema</eplink>) </li><li class="li"> central nervous system injury (<eplink linkfield="AN" linkkey="T922924">neurogenic pulmonary edema</eplink>) </li><li class="li"> ischemic/reperfusion injury after <eplink linkfield="AN" linkkey="T922145">lung transplant</eplink><sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>)</sups></sc></li><li class="li"> rapid removal of air or fluid from pleural cavity, such as during <eplink linkfield="AN" linkkey="T909468">thoracentesis</eplink> (re-expansion edema)<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>)</sups></sc></li><li class="li"> capillary leak syndrome, causes of which include <ul class="ul"><li class="li"> idiopathic systemic capillary leak syndrome (Clarkson disease) </li><li class="li"> medications, such as interleukin-2, gemcitabine, or monoclonal antibodies </li><li class="li"> engraftment syndrome after hematopoietic stem cell transplant </li><li class="li"> retinoic acid (differentiation syndrome) </li><li class="li"> ovarian hyperstimulation syndrome </li><li class="li"> hemophagocytic lymphohistiocytosis </li><li class="li"> viral hemorrhagic fever </li><li class="li"> autoimmune diseases </li><li class="li"> snakebite envenomation </li><li class="li"> ricin poisoning </li><li class="li"> Reference - <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28318633?dopt=Abstract" target="%5Fblank"> Kidney Int 2017 Jul;92(1):37</a></li></ul></li></ul></li> </ul> </section> </section> <section id="sec-Mimics"> <h3 id="Mimics">Mimics</h3> <anchor name="Mimics"></anchor> <ul class="ul"> <li class="li"> <eplink linkfield="AN" linkkey="T913128">diffuse alveolar hemorrhage</eplink> <sc> <sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups> </sc> </li> <li class="li"> bronchoalveolar carcinoma<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li> <li class="li"> other types of fluid accumulation<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>)</sups></sc><ul class="ul"><li class="li"> anasarca </li><li class="li"> ascites </li><li class="li"> bilateral pleural effusion </li></ul></li> </ul> </section> </section> <section id="sec-Pathogenesis" collapsible="true" bullettype="arrow"> <h2 id="Pathogenesis">Pathogenesis</h2> <anchor name="Pathogenesis"></anchor> <section id="sec-Normal-fluid-exchange"> <h3 id="Normal-fluid-exchange">Normal fluid exchange</h3> <anchor name="Normal-fluid-exchange"></anchor> <ul class="ul"> <li class="li">
 discussion of mechanisms of pulmonary edema formation may be framed in 
context of Starling's equation, which describes transendothelial fluid 
exchange in pulmonary capillary endothelium<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>, <a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3105">3</a>)</sups></sc><ephtml><div class="TableModal_modalContent" data-auto="table-details"><table class="table" frame="border" rules="all" summary="" id="ID0EXIAC" cellspacing="0" cellpadding="4" border="1"><colgroup><col style="width:100%"></colgroup><tbody><tr class="row"><td class="entry cellrowborder">Q<small><sub>f</sub></small> = K<small><sub>f </sub></small>([P<small><sub>c </sub></small> - P<small><sub>i </sub></small>] - σ[π<small><sub>c </sub></small> - π<small><sub>i </sub></small>])<ul><li>Q<small><sub>f </sub></small> is net fluid movement from capillary lumen to alveolar interstitium</li><li>[P<small><sub>c </sub></small> - P<small><sub>i </sub></small>] is hydrostatic pressure where c is capillary and i is interstitial</li><li>σ is reflection coefficient indicating endothelial permeability to proteins</li><li>[π<small><sub>c </sub></small> - π<small><sub>i </sub></small>] is oncotic pressure where c is capillary and i is interstitial</li><li>K<small><sub>f </sub></small> is coefficient of capillary permeability (includes hydraulic conductivity and filtration surface area)</li></ul></td></tr></tbody></table></div></ephtml></li> <li class="li"> in normal lung <ul class="ul"><li class="li"> permeability of endothelium to both water and protein determines volume of fluid that forms at any given net force<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>)</sups></sc></li><li class="li">
 hydrostatic pressure favors net fluid flow from capillaries to 
interstitium, with subsequent fluid drainage through pulmonary 
lymphatics<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>, <a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3105">3</a>)</sups></sc></li><li class="li"> oncotic pressure<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc><ul class="ul"><li class="li">
 endothelial glycocalyx (network of glycosaminoglycans and proteins 
lining pulmonary capillary endothelium) collects serum plasma proteins, 
forming ultrafiltrate layer between endothelium and glycocalyx </li><li class="li"> ultrafiltrate layer generates oncotic force, pulling fluid into intravascular compartment </li></ul></li></ul></li> <li class="li"> formula for estimating pulmonary capillary hydrostatic pressure using left atrial pressure<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc><ephtml><div class="TableModal_modalContent" data-auto="table-details"><table class="table" frame="border" rules="all" summary="" id="ID0E1LAC" cellspacing="0" cellpadding="4" border="1"><colgroup><col style="width:100%"></colgroup><tbody><tr class="row"><td class="entry cellrowborder">P<small><sub>mv</sub></small> = P<small><sub>La</sub></small> + 0.4(MPAP-P<small><sub>La</sub></small>)<ul><li>P<small><sub>mv </sub></small> is pulmonary capillary hydrostatic pressure</li><li>P<small><sub>La</sub></small> is left atrial pressure</li><li>MPAP is mean pulmonary pressure</li></ul></td></tr></tbody></table></div></ephtml></li> </ul> </section> <section id="sec-Mechanisms-of-edema-formation"> <h3 id="Mechanisms-of-edema-formation">Mechanisms of edema formation</h3> <anchor name="Mechanisms-of-edema-formation"></anchor> <ul class="ul"> <li class="li"> general causes of edema formation <ul class="ul"><li class="li"> in hydrostatic edema<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>, <a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc><ul class="ul"><li class="li">
 left atrial and pulmonary capillary pressure rises following left 
ventricular pressure increase (such as in left ventricle failure) or 
volume overload </li><li class="li"> pressure increase causes increased 
wall tension in capillaries leading to increased fluid flow into 
interstitium, eventually surpassing drainage capacity of pulmonary 
lymphatics </li><li class="li"> extravascular lung water accumulates, followed by formation of alveolar edema</li><li class="li">hydrostatic pressure is opposed by colloid osmotic pressure in capillaries (primarily driven by albumin)</li></ul></li><li class="li">
 in permeability edema, damage to ultrafiltrate layer created by 
endothelial glycocalyx that lines pulmonary capillary endothelium (such 
as in surgical trauma or ischemic/reperfusion injury) increases 
capillary permeability, leading to increased extravasation of 
protein-rich fluid and subsequent edema<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc></li></ul></li> <li class="li"> stages of pulmonary fluid accumulation and edema development<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc><ul class="ul"><li class="li"> stage 1 (compensated) - increased fluid accumulation with parallel increase in lymphatic flow; no net fluid accumulation </li><li class="li">
 stage 2 (perihilar edema) - fluid accumulation overwhelms lymphatic 
drainage and edema develops around bronchioles and lung vasculature </li><li class="li"> stage 3 (alveolar edema) <ul class="ul"><li class="li"> interstitial fluid continues to accumulate around periphery of alveolar membrane </li><li class="li"> over time fluid crosses alveolar wall, leading to alveolar flooding </li></ul></li></ul></li> </ul> </section> <section id="sec-Mechanisms-of-edema-resolution"> <h3 id="Mechanisms-of-edema-resolution">Mechanisms of edema resolution</h3> <anchor name="Mechanisms-of-edema-resolution"></anchor> <ul class="ul"> <li class="li"> vectorial ion transplant is primary driver of pulmonary edema resolution <ul class="ul"><li class="li"> osmotic gradient for reabsorption of water from alveoli into interstitium is created <ul class="ul"><li class="li">
 sodium ions taken up by apical sodium channels on alveolar epithelial 
type 1 and 2 cells, with subsequent passage into lung interstitium via 
sodium-potassium ATPase<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3105">3</a>)</sups></sc></li><li class="li">
 chloride ion transport mediated by cystic fibrosis transmembrane 
conductance regulator (CFTR), which is expressed on apical membranes of 
distal airway and alveolar epithelial cells (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28439270?dopt=Abstract" target="%5Fblank"> Front Immunol 2017;8:393</a> <a class="link internal jump-link" href="https://www.frontiersin.org/articles/10.3389/fimmu.2017.00393/full#F1" target="%5Fblank">full-text</a>) </li></ul></li><li class="li"> water passively follows ions through aquaporins (water channels found mainly on alveolar epithelial type I cells)<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> fluid moved to interstitium subsequently drained via pulmonary lymphatics<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3105">3</a>)</sups></sc></li></ul></li> </ul> </section> </section> <section id="sec-General-Evaluation" collapsible="true" bullettype="arrow"> <h2 id="General-Evaluation">General Evaluation</h2> <anchor name="General-Evaluation"></anchor> <section id="sec-Clinical-presentation"> <h3 id="Clinical-presentation">Clinical presentation</h3> <anchor name="Clinical-presentation"></anchor> <ul class="ul"> <li class="li">clinical presentation is variable, and features of cardiogenic and noncardiogenic edema can overlap<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>)</sups></sc></li> <li class="li">acute pulmonary edema usually presents as medical emergency, and symptoms can include<ul class="ul"><li class="li"> severe, rapidly-progressive dyspnea<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>, <a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li><li class="li"> tachypnea<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>, <a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc></li><li class="li"> orthopnea<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc></li><li class="li"> pink frothy sputum (in endotracheal tube if intubated; or as expectoration)<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3105">3</a>, <a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li></ul></li> <li class="li"> patients may also present with sympathetic nervous system activation that can manifest as<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc><ul class="ul"><li class="li"> tachycardia </li><li class="li"> cold skin </li><li class="li"> pallor </li><li class="li"> sweating </li></ul></li> <li class="li"> patients often present with acute symptoms in middle of night<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li> <li class="li"> physical examination and laboratory testing may show <ul class="ul"><li class="li"> hypoxemia<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>, <a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li><li class="li"> hypertension<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li><li class="li"> crackles (rales) on lung auscultation (typically best heard in posterior basilar regions in supine patients)<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc></li></ul></li> </ul> </section> <section id="sec-Diagnostic-approach"> <h3 id="Diagnostic-approach">Diagnostic approach</h3> <anchor name="Diagnostic-approach"></anchor> <section id="sec-Initial-evaluation"> <h4 id="Initial-evaluation" level="1">Initial evaluation</h4> <anchor name="Initial-evaluation"></anchor> <ul class="ul"> <li class="li">
 in patients with acute pulmonary edema, initial assessment to determine
 cardiogenic or noncardiogenic cause should include clinical history, 
physical examination, laboratory testing, and chest x-ray <ul class="ul"><li class="li"> history, physical exam, and laboratory testing findings <ul class="ul"><li class="li"> for cardiogenic edema <ul class="ul"><li class="li"> history of <ul class="ul"><li class="li">valvular disease<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>)</sups></sc></li><li class="li">tachyarrhythmia<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li><li class="li"> myocardial infarction or congestive heart failure<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> recent transfusion with blood, blood products, or fluids<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679">1</a>, <a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc></li><li class="li"> uncontrolled hypertension or high salt intake<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc></li></ul></li><li class="li"> low cardiac output state<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> third heart sound on auscultation<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> peripheral edema<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> jugular venous distension<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> elevated cardiac enzymes (such as troponin)<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> elevated brain natriuretic peptide levels<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li></ul></li><li class="li"> for noncardiogenic edema <ul class="ul"><li class="li"> history of <ul class="ul"><li class="li"> infection (pulmonary or nonpulmonary)<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> aspiration or other cause of upper airway obstruction<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> ascent to high elevation<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc></li><li class="li"> central nervous system injury<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc></li><li class="li"> recent lung transplant causing ischemic/reperfusion injury<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc></li><li class="li"> medication or therapy known to cause capillary leak syndrome (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28318633?dopt=Abstract" target="%5Fblank"> Kidney Int 2017 Jul;92(1):37</a>) </li></ul></li><li class="li"> hyperdynamic state<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> elevated white blood cell count<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> laboratory findings suggestive of <eplink linkfield="AN" linkkey="T127664">pancreatitis</eplink> or <eplink linkfield="AN" linkkey="T115066">peritonitis</eplink><sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li><li class="li"> normal brain natriuretic peptide levels<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li></ul></li><li class="li"> see <eplink linkfield="AN" linkkey="T146524">Natriuretic peptide and biomarkers testing for heart failure</eplink> and <eplink linkfield="AN" linkkey="T115680">Cardiac troponin testing</eplink> for additional information </li></ul></li><li class="li"> chest x-ray <ephtml><div class="TableModal_modalContent" data-auto="table-details"><table class="table" frame="border" rules="all" summary="" id="ID0ERMAE" cellspacing="0" cellpadding="4" border="1"><caption>Typical Chest X-ray Findings in Types of Edema:</caption><colgroup><col style="width:35%"><col style="width:33%"><col style="width:32%"></colgroup><tbody><tr class="row"><th class="entry cellrowborder" id="d30e1676"> Type of Finding</th><th class="entry cellrowborder" id="d30e1679"> Appearance in Cardiogenic Edema</th><th class="entry cellrowborder" id="d30e1682">Appearance in Noncardiogenic Edema</th></tr><tr class="row"><td class="entry cellrowborder">Heart size</td><td class="entry cellrowborder">Enlarged</td><td class="entry cellrowborder">Normal</td></tr><tr class="row"><td class="entry cellrowborder">Vascular pedicle width</td><td class="entry cellrowborder"> &amp;gt; 70 mm</td><td class="entry cellrowborder"> ≤ 70 mm</td></tr><tr class="row"><td class="entry cellrowborder">Pulmonary blood flow</td><td class="entry cellrowborder">Inverted (cephalized)</td><td class="entry cellrowborder">Normal or balanced</td></tr><tr class="row"><td class="entry cellrowborder">Pulmonary blood volume</td><td class="entry cellrowborder">Normal or increased</td><td class="entry cellrowborder">Normal</td></tr><tr class="row"><td class="entry cellrowborder">Distribution of pulmonary infiltrates</td><td class="entry cellrowborder">Central</td><td class="entry cellrowborder">Peripheral</td></tr><tr class="row"><td class="entry cellrowborder">Kerley lines</td><td class="entry cellrowborder">Present</td><td class="entry cellrowborder">Not present</td></tr><tr class="row"><td class="entry cellrowborder">Peribronchial cuffing</td><td class="entry cellrowborder">Common</td><td class="entry cellrowborder">Uncommon</td></tr><tr class="row"><td class="entry cellrowborder">Pleural effusion</td><td class="entry cellrowborder">Common</td><td class="entry cellrowborder">Uncommon</td></tr><tr class="row"><td class="entry cellrowborder">Air bronchogram</td><td class="entry cellrowborder">Uncommon</td><td class="entry cellrowborder">Common</td></tr><tr class="row"><td class="entry cellrowborder" colspan="3"> Reference - <small><sup>(<a href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>, <a href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sup></small>. </td></tr></tbody></table></div></ephtml><img src="Pulmonary%20Edema%20-%20Approach%20to%20the%20Patient_files/I510576.jpg" alt="I510576.jpg" title="Diagram of vascular pedicle. : The vascular pedicle is bordered on the right by venous structures (right brachiocephalic vein above and superior vena cava) and on the left by an arterial structure (the left subclavian artery origin). The azygos vein (black oval) is seen en face above the right main bronchus. The vascular pedicle width (VPW) is the distance between parallel lines drawn from the point at which the superior vena cava intersects the right main bronchus and a line drawn at the takeoff of the left subclavian artery from the aorta. The mean vascular pedicle width is 38-58 mm on posteroanterior chest radiographs."><ul class="ul"><li class="li">
 in patients with acute heart failure, chest x-ray findings suggestive 
of edema may not appear for up to 12 hours after initial clinical 
presentation and may persist for 1-4 days after clinical improvement<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc><img src="Pulmonary%20Edema%20-%20Approach%20to%20the%20Patient_files/I502093.jpg" alt="I502093.jpg" title="Pulmonary edema radiograph. : This chest radiograph shows cardiomegaly and bilateral perihilar alveolar infiltrates, consistent with a diagnosis of acute pulmonary edema due to heart failure. A small left pleural effusion is seen, as well as fluid in the minor fissure, also consistent with heart failure."><img src="Pulmonary%20Edema%20-%20Approach%20to%20the%20Patient_files/GUID-59A65031-0A4F-48C0-9703-77C16A71A9D2-printquality.html" alt="GUID-59A65031-0A4F-48C0-9703-77C16A71A9D2-printquality.png" title="Chest x-ray and CT with batwing sign. : A frontal chest radiograph and axial CT show features of ‘batwing’ alveolar pulmonary edema. Chest radiographic findings include bilateral opacities that extend in a fan shape outward from the hilum in a batwing pattern (arrows). With worsening alveolar edema, the lung opacification becomes increasingly homogenous. Abbreviation: CT, computed tomography."></li></ul></li></ul></li> </ul> </section> <section id="sec-Additional-evaluation"> <h4 id="Additional-evaluation" level="1">Additional evaluation</h4> <anchor name="Additional-evaluation"></anchor> <section id="sec-Lung-ultrasound"> <h4 id="Lung-ultrasound" level="2">Lung ultrasound</h4> <anchor name="Lung-ultrasound"></anchor> <ul class="ul"> <li class="li">
 bedside lung ultrasound in emergency (BLUE) protocol can be used to 
diagnose acute respiratory failure or when physical examination 
inconclusive in patients with respiratory distress <ul class="ul"><li class="li"> signs seen in fluid accumulation <ul class="ul"><li class="li">
 B-lines (forming lung rockets if ≥ 3 between 2 ribs) - presence rules 
out pneumothorax; lung rockets associated with interstitial syndrome 
(such as pulmonary edema)<img src="Pulmonary%20Edema%20-%20Approach%20to%20the%20Patient_files/I509084.png" alt="I509084.png" title="B-lines. : 4 or 5 B-lines are visible, called lung rockets (here septal rockets correlating with thickened subpleural interlobular septa)."><ul class="ul"><li class="li"> always comet-tail artifact </li><li class="li"> always arises from pleural line </li><li class="li"> always moves simultaneously with lung sliding </li><li class="li"> typically long and extending to lower edge of screen </li><li class="li"> typically hyperechoic like pleural line </li><li class="li"> typically well-defined </li><li class="li"> typically obliterates A-lines </li></ul></li><li class="li">
 sinusoid sign - in free pleural effusions, visceral pleura lung line 
moves toward pleural line during inspiration, creating sinusoid sign; 
together with quad sign associated with pleural effusion<img src="Pulmonary%20Edema%20-%20Approach%20to%20the%20Patient_files/I509087.png" alt="I509087.png" title="Sinusoid sign. : M-mode shows a movement of the lung line (white arrows) toward the pleural line (black arrows) on inspiration - the sinusoid sign, indicating also a free pleural effusion, and a viscosity enabling the use of small caliper needle if thoracentesis is to be performed."></li><li class="li">
 fractal (or shred) sign - pleural effusion with identifiable visceral 
pleura lung line with shredded deep border underneath; associated with 
nontranslobular consolidations <img src="Pulmonary%20Edema%20-%20Approach%20to%20the%20Patient_files/I509090.png" alt="I509090.png" title="Fractal sign. : A middle lobe consolidation, which does not involve the whole lobe. This generates a shredded, fractal boundary between the consolidation and the underlying aerated lung (arrows): the quite specific shred (or fractal) sign. Such an anterior consolidation generates the C-profile in the BLUE-protocol."></li></ul></li><li class="li"><ephtml><div class="TableModal_modalContent" data-auto="table-details"><table class="table" frame="border" rules="all" summary="" id="ID0EZRAE" cellspacing="0" cellpadding="4" border="1"><caption>Typical Lung Ultrasound Features by Type of Edema:</caption><colgroup><col style="width:50%"><col style="width:50%"></colgroup><tbody><tr class="row"><th class="entry cellrowborder" id="d30e2031">Type of Edema </th><th class="entry cellrowborder" id="d30e2034"> Typical Lung Ultrasound Features</th></tr><tr class="row"><td class="entry cellrowborder">Cardiogenic</td><td class="entry cellrowborder"><ul><li> Ground glass rockets (B lines) </li><li> Thin, even pleural line </li><li> Normal lung sliding </li><li> Homogenous lung tissue </li><li> Transudative appearance of pleural effusion </li></ul></td></tr><tr class="row"><td class="entry cellrowborder">Noncardiogenic</td><td class="entry cellrowborder"><ul><li> Ground glass rockets (B lines) </li><li> Thick, uneven pleural line </li><li> Heterogenous lung tissue </li><li> Spared areas </li><li> Tissue consolidations </li><li> Air bronchograms </li><li> Lung pulse </li><li> Exudative appearance of pleural effusion </li></ul></td></tr><tr class="row"><td class="entry cellrowborder" colspan="2"> Reference - <small><sup>(<a href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sup></small>. </td></tr></tbody></table></div></ephtml></li><li class="li"> see <eplink linkfield="AN" linkkey="T909624">Ultrasound in the intensive care unit (ICU)</eplink> for additional information </li></ul></li> </ul> </section> <section id="sec-Transthoracic-echocardiography--TTE"> <h4 id="Transthoracic-echocardiography--TTE" level="2">Transthoracic echocardiography (TTE)</h4> <anchor name="Transthoracic-echocardiography--TTE"></anchor> <ul class="ul"> <li class="li"> TTE usually obtained in the evaluation of patients with pulmonary edema to determine underlying cause<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc><ul class="ul"><li class="li"> cardiogenic edema <ul class="ul"><li class="li">
 suggested by presence of enlarged cardiac chambers and/or decreased 
left ventricular function, although normal findings do not rule out 
cardiogenic cause </li><li class="li"> may indicate <ul class="ul"><li class="li"><eplink linkfield="AN" linkkey="T114099">heart failure with reduced ejection fraction</eplink>, as can be seen in patients with <ul class="ul"><li class="li"> ischemic cardiomyopathy </li><li class="li"><eplink linkfield="AN" linkkey="T114780">dilated cardiomyopathy</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T115915">peripartum cardiomyopathy</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T901072">takotsubo syndrome</eplink></li></ul></li><li class="li"><eplink linkfield="AN" linkkey="T114748">restrictive cardiomyopathy</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T193266">heart failure with preserved ejection fraction</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T115426">hypertrophic cardiomyopathy</eplink></li></ul></li></ul></li><li class="li"> noncardiogenic edema suggested by normal or small cardiac chamber size and normal left ventricular function </li><li class="li"><emph>DynaMed commentary -- </emph>Some
 patients with noncardiogenic pulmonary edema from acute respiratory 
distress syndrome and sepsis may have dilated cardiac chambers and left 
ventricular dysfunction. </li></ul></li> </ul> </section> <section id="sec-Electrocardiogram--ECG"> <h4 id="Electrocardiogram--ECG" level="2">Electrocardiogram (ECG)</h4> <anchor name="Electrocardiogram--ECG"></anchor> <ul class="ul"> <li class="li"> if suspected cardiogenic edema due to heart failure, consider ECG to identify potential cause <ul class="ul"><li class="li">
 abnormal ECG has limited positive predictive value for heart failure, 
but completely normal ECG makes heart failure with systolic function 
unlikely (&lt; 10%) </li><li class="li"> common ECG abnormalities in heart failure and potential causes <ul class="ul"><li class="li"> sinus tachycardia - decompensated heart failure, anemia, fever, hyperthyroidism </li><li class="li">
 sinus bradycardia - beta blocker, digoxin, ivabradine, verapamil, 
diltiazem, anti-arrhythmic, hypothyroidism, sick sinus syndrome </li><li class="li"> atrial tachyarrhythmia - hyperthyroidism, infection, mitral valve disease, decompensated heart failure, infarction </li><li class="li"> ventricular arrhythmia - ischemia, infarction, cardiomyopathy, myocarditis, hypokalemia, hypomagnesemia, digitalis overdose </li><li class="li"> myocardial ischemia/infarction - coronary artery disease </li><li class="li">
 atrioventricular block - infarction, drug toxicity, myocarditis, 
sarcoidosis, Lyme disease, genetic cardiomyopathy (such as laminopathy, 
desminopathy) </li><li class="li"> Q waves - infarction, hypertrophic cardiomyopathy, left bundle branch block, preexcitation </li><li class="li"> QRS &gt; 120 milliseconds with left bundle branch block morphology - electromechanical dyssynchrony </li><li class="li"> left ventricular hypertrophy - hypertension, aortic valve disease, hypertrophic cardiomyopathy </li><li class="li"> microvoltage - obesity, emphysema, pericardial effusion, amyloidosis </li></ul></li><li class="li"> ambulatory ECG monitoring may be useful if <ul class="ul"><li class="li"> symptoms suggestive of arrhythmia or bradycardia, such as palpitations or syncope </li><li class="li"> atrial fibrillation, to monitor ventricular rate </li></ul></li><li class="li"> Reference - <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22611136?dopt=Abstract" target="%5Fblank"> Eur Heart J 2012 Jul;33(14):1787</a></li></ul></li> <li class="li"> see <eplink linkfield="AN" linkkey="T114879">Acute heart failure</eplink>, <eplink linkfield="AN" linkkey="T114099">Heart failure with reduced ejection fraction</eplink>, and <eplink linkfield="AN" linkkey="T193266">Heart failure with preserved ejection fraction</eplink> for additional information </li> </ul> </section> <section id="sec-Pulmonary-artery-catheterization"> <h4 id="Pulmonary-artery-catheterization" level="2">Pulmonary artery catheterization</h4> <anchor name="Pulmonary-artery-catheterization"></anchor> <ul class="ul"> <li class="li">
 pulmonary artery catheterization not routinely used, but can be 
considered in patients with uncertain diagnosis after initial assessment
 and testing<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li> <li class="li"> consider cardiogenic edema if pulmonary artery occlusion pressure &gt; 18 mm Hg and noncardiogenic edema if ≤ 18 mm Hg<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113">5</a>)</sups></sc></li> <li class="li"> catheterization allows for performance of transpulmonary thermodilution procedure to assess cardiac output<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924">2</a>)</sups></sc><ul class="ul"><li class="li">
 involves injection of cold saline bolus into central venous circulation
 with subsequent measurement of change in blood temperature </li><li class="li">
 establishes thermodilution curve that allows for calculation of 
hemodynamic variables (such as cardiac index or extravascular lung water
 index) </li><li class="li"> assumes homogenous distribution of 
pulmonary perfusion and accuracy may be dependent upon factors affecting
 ventilation/perfusion relationship, such as hypoxic pulmonary 
vasoconstriction, lung injury, vascular obstruction, positive 
end-expiratory pressure, spontaneous breathing, or lung resection </li></ul></li> <li class="li"> see <eplink linkfield="AN" linkkey="T909970">Hemodynamic monitoring</eplink> and <eplink linkfield="AN" linkkey="T113684">Pulmonary artery catheter</eplink> for additional information </li> </ul> </section> </section> </section> </section> <section id="sec-Management" collapsible="true" bullettype="arrow"> <h2 id="Management">Management</h2> <anchor name="Management"></anchor> <section id="sec-Acute-management"> <h3 id="Acute-management">Acute management</h3> <anchor name="Acute-management"></anchor> <ul class="ul"> <li class="li">
 primary goal in acute pulmonary edema is to reduce pulmonary fluid 
levels by shifting fluid from lung tissue to systemic circulation 
through any of the following<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc><ul class="ul"><li class="li"> reducing pulmonary capillary hydrostatic pressure (can be achieved using vasodilators) </li><li class="li"> increasing lymphatic drainage by reducing systemic venous pressure (can be achieved using vasodilators) </li><li class="li">
 redistributing fluid from alveoli into lymphatics (can be partially 
achieved by ventilatory support with positive end expiratory pressure) </li><li class="li"> altering capillary permeability </li></ul></li> <li class="li"> therapies to consider for management of acute pulmonary edema<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3105">3</a>, <a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc><ul class="ul"><li class="li"> oxygenation and ventilatory support <ul class="ul"><li class="li"> oxygen is usually provided if patient is hypoxemic and no contraindications due to risk of carbon dioxide retention </li><li class="li">
 positive end-expiratory pressure (PEEP) (using either noninvasive or 
invasive ventilation) to improve gas exchange, reduce work of breathing,
 and directly redistribute fluid from alveoli into pulmonary lymphatics 
for drainage </li><li class="li"><eplink linkfield="AN" linkkey="T483077">positive pressure ventilation </eplink>to reduce venous return and wedge pressure</li></ul></li><li class="li"> medications <ul class="ul"><li class="li"> intravenous loop diuretics (e.g. furosemide) given routinely to reduce circulating fluid volume </li><li class="li"> vasodilators (such as nitrate therapy or ACE inhibitors) to reduce left ventricular filling pressure </li><li class="li"> inotropic support if low cardiac output and/or blood pressure and patient resistant to initial therapy </li></ul></li><li class="li"> conflicting recommendations on use of opiates, such as morphine, to relieve distress, anxiety, pain, and dyspnea<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535">4</a>)</sups></sc><ul class="ul"><li class="li"> morphine is venodilator and weak arterial vasodilator that suppresses feeling of air hunger (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/17353535?dopt=Abstract" target="%5Fblank"> CMAJ. 2007 Mar 13;176(6):797-805</a> <a class="link internal jump-link" href="http://www.cmaj.ca/content/176/6/797.full" target="%5Fblank">full-text</a>) </li><li class="li"> in patients with severe dyspnea, opiates may be considered to relieve dyspnea and anxiety but nausea and hypopnea may occur (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class IIb, Level B</a>) (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27206819?dopt=Abstract" target="%5Fblank"> Eur Heart J. 2016 Jul 14;37(27):2129-200</a> <a class="link internal jump-link" href="https://academic.oup.com/eurheartj/article/37/27/2129/1748921" target="%5Fblank">full-text</a>) </li><li class="li"> do not routinely offer opiates to patients with acute heart failure (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/25340219?dopt=Abstract" target="%5Fblank"> NICE Acute Heart failure: diagnosis and management 2014 Oct</a>) </li><li class="li"><bold>IV
 opiates may not be associated with reduced dyspnea in patients with 
cardiogenic pulmonary edema (level 2 [mid-level] evidence)</bold><ul class="ul"><li class="li"> based on retrospective cohort study </li><li class="li"> 1,052 patients (51.4% of whom received IV opiates) with cardiogenic pulmonary edema included </li><li class="li"> opiates not associated with improvement in dyspnea as measured by visual analog scale compared to no opiates </li><li class="li"> mortality 10.4% with opiates vs. 8.8% with no opiates (not significant) </li><li class="li"> Reference - <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/20511258?dopt=Abstract" target="%5Fblank"> QJM 2010 Aug;103(8):573</a> <a class="link internal jump-link" href="https://academic.oup.com/qjmed/article/103/8/573/1522679" target="%5Fblank">full-text</a></li></ul></li></ul></li></ul></li> </ul> </section> <section id="sec-Management-of-common-causes-of-pulmonary-edema"> <h3 id="Management-of-common-causes-of-pulmonary-edema">Management of common causes of pulmonary edema</h3> <anchor name="Management-of-common-causes-of-pulmonary-edema"></anchor> <section id="sec-Acute-cardiogenic-pulmonary-edema"> <h4 id="Acute-cardiogenic-pulmonary-edema" level="1">Acute cardiogenic pulmonary edema</h4> <anchor name="Acute-cardiogenic-pulmonary-edema"></anchor> <section id="sec-Acute-heart-failure"> <h4 id="Acute-heart-failure" level="2">Acute heart failure</h4> <anchor name="Acute-heart-failure"></anchor> <ul class="ul"> <li class="li"> management of patients with acute heart failure<ul class="ul"><li class="li">
 high-flow oxygen recommended in patients with capillary oxygen 
saturation &lt; 90% or partial pressure of oxygen in arterial blood (PaO<sc><subs>2</subs></sc>) &lt; 60 mm Hg (8 kilopascals [kPa]) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class I Level C</a>) </li><li class="li"> fluid management <ul class="ul"><li class="li"> IV loop diuretics recommended if evidence of significant fluid overload (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level B</a>) to improve breathlessness and relieve congestion (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class I, Level C</a>) <ul class="ul"><li class="li"> for example, furosemide (Lasix) 40-100 mg IV bolus, double dose in 30 minutes if no effect </li><li class="li"> increase dose or add second diuretic (for example, a thiazide) if inadequate to relieve congestion (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIa, Level B</a>) </li><li class="li"> monitor symptoms, urine output, renal function, and electrolytes during use of IV diuretics (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class I, Level C</a>) </li><li class="li"> continuous infusion of loop diuretics appears no more effective than intermittent boluses (level 2 [mid-level] evidence) </li><li class="li"> see <eplink linkfield="AN" linkkey="T901136">Diuretics for heart failure</eplink> for complete information </li></ul></li><li class="li"> conflicting recommendations on use of low-dose dopamine <ul class="ul"><li class="li">
 European Society of Intensive Care Medicine (ESICM) recommends against 
use of low-dose dopamine for protection against acute kidney injury in 
the critically ill (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESICM2017GRADE">ESICM Grade 1A</a>) (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28577069?dopt=Abstract" target="%5Fblank"> Intensive Care Med 2017 Jun;43(6):730</a> <a class="link internal jump-link" href="https://link.springer.com/article/10.1007%2Fs00134-017-4832-y" target="%5Fblank">full-text</a>) </li><li class="li">
 American College of Cardiology recommends that low-dose dopamine 
infusion may be considered in addition to loop diuretic therapy for 
improvement of diuresis in patients with decompensated heart failure (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIb, Level B</a>) </li></ul></li><li class="li">
 vasodilators (IV nitroglycerin, nitroprusside, or nesiritide) may be 
considered as adjunct to diuretics to relieve dyspnea in patients with 
acutely decompensated heart failure in absence of symptomatic 
hypotension (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIb, Level A</a>) <ul class="ul"><li class="li">
 nesiritide (Natrecor) may not reduce mortality, rehospitalization, or 
dyspnea in patients with acute decompensated heart failure (level 2 
[mid-level] evidence) and increases risk for hypotension </li><li class="li"> nitrates for acute heart failure syndrome have insufficient evidence for effects on clinical outcomes </li></ul></li><li class="li"> consider ultrafiltration for refractory congestion (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIa, Level C</a>),
 but comparisons with diuresis have inconsistent results including 
increased risk for serious adverse events (level 2 [mid-level] evidence)
 </li></ul></li><li class="li"> ventilatory support <ul class="ul"><li class="li">
 consider noninvasive ventilation in patients with respiratory distress 
(respiratory rate &gt; 25 breaths/minute, transcutaneous oxygen 
saturation &lt; 90%) and start as early as possible to improve 
breathlessness and reduce rate of mechanical endotracheal intubation (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class IIa, Level B</a>) <ul class="ul"><li class="li"> use with caution in hypotensive patients as it may reduce blood pressure </li><li class="li"> monitor blood pressure regularly when treatment used </li></ul></li><li class="li"> see <eplink linkfield="AN" linkkey="T483077">Noninvasive positive pressure ventilation (NPPV) in adults</eplink> for complete information </li><li class="li"> intubation recommended if unable to noninvasively manage respiratory failure leading to (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class I, Level C</a>) <ul class="ul"><li class="li"> hypoxemia (partial pressure of oxygen in arterial blood &lt; 60 mm Hg [8 kilopascal]) </li><li class="li"> hypercapnia (partial pressure of carbon dioxide in arterial blood &gt; 50 mm Hg [6.65 kilopascal]) </li><li class="li"> acidosis (pH &lt; 7.35) </li></ul></li></ul></li><li class="li">
 IV opiates (for example, morphine) may be considered in patients with 
severe dyspnea and anxiety, but nausea and hypopnea may occur (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class IIb, Level B</a>) </li><li class="li">
 consider short-term, continuous IV inotropic support (such as dopamine,
 dobutamine, or milrinone) in hospitalized patients with documented 
severe systolic dysfunction, low blood pressure, and significantly 
depressed cardiac output (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIb, Level B</a>) </li><li class="li">
 monitor fluid intake and output, weight, serum electrolytes, blood urea
 nitrogen (BUN), and creatinine daily during use of IV diuretics or 
active medication titration (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level C</a>) </li><li class="li"> invasive hemodynamic monitoring <ul class="ul"><li class="li">
 recommended to guide therapy if respiratory distress or clinical 
evidence of impaired perfusion with inability to assess intracardiac 
filling pressures clinically (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level C</a>) </li><li class="li">
 pulmonary artery catheterization may increase adverse events (level 2 
[mid-level] evidence) and does not reduce mortality or length of 
hospitalization (level 1 [likely reliable] evidence) </li></ul></li><li class="li">
 during symptomatic exacerbation of heart failure requiring 
hospitalization in patients on chronic maintenance treatment with 
guideline-directed medical therapy, continuation of guideline-directed 
medical therapy recommended in absence of hemodynamic instability or 
contraindications (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level B</a>) ( <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/23741058?dopt=Abstract" target="%5Fblank"> Circulation 2013 Oct 15;128(16):e240</a>) </li></ul></li> <li class="li"> see also <ul class="ul"><li class="li"><eplink linkfield="AN" linkkey="T114879">Acute heart failure</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T115657">Cardiogenic shock</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T116779">Acute coronary syndromes</eplink></li><li class="li"><eplink linkfield="AN" linkkey="T193266">Heart failure with preserved ejection fraction</eplink></li></ul></li> </ul> </section> <section id="sec-Transfusion-associated-pulmonary-edema"> <h4 id="Transfusion-associated-pulmonary-edema" level="2">Transfusion-associated pulmonary edema</h4> <anchor name="Transfusion-associated-pulmonary-edema"></anchor> <ul class="ul"> <li class="li"> in patients with transfusion-associated pulmonary edema <ul class="ul"><li class="li"> if acute transfusion-associated reaction occurs <ul class="ul"><li class="li"> halt or restrict transfusion </li><li class="li"> manage symptoms with supportive care and monitoring <ul class="ul"><li class="li">
 supportive care includes supplemental oxygen, elevation of head of bed,
 and prescription of diuretics and nitrates as patient's hemodynamics 
allow </li><li class="li"> monitoring includes continuous pulse oximetry, cardiac telemetry, and strict monitoring of urine output following diuretics </li><li class="li">
 mechanical ventilation is required in most cases in accordance with 
clinical presentation, and has been reported to have been used in 
70%-90% of patients with transfusion-related acute lung injury (TRALI) </li><li class="li"> renal replacement therapy may be necessary in patients with severe renal impairment </li></ul></li></ul></li><li class="li"> once initial reaction stabilized <ul class="ul"><li class="li"> evaluate and manage based on clinical presentation <ul class="ul"><li class="li"> determination of etiology of pulmonary edema essential for establishing respiratory and diuretic management <ul class="ul"><li class="li">
 if TRALI or possible TRALI, consider low tidal volume strategy via 
invasive mechanical ventilation with maintenance of normovolemia </li><li class="li">
 if transfusion-associated circulatory overload (TACO), consider 
aggressive diuretic therapy and noninvasive ventilation based on 
cardiopulmonary status </li></ul></li><li class="li"> if suspected sepsis, assess and manage accordingly based on age of patient (<eplink linkfield="AN" linkkey="T316889">adult</eplink> or <eplink linkfield="AN" linkkey="T270047">child</eplink>) while waiting for confirmation via Gram stain and blood transfusion bag cultures and patient blood cultures </li><li class="li"> if suspected <eplink linkfield="AN" linkkey="T113858">anaphylaxis</eplink>, assess and manage accordingly </li><li class="li"> if suspected allergic reaction, look for urticaria and erythema of face and trunk, and manage accordingly </li><li class="li"> if chest x-ray shows presence of pulmonary edema, suspect TRALI and/or TACO (both can occur simultaneously) </li><li class="li">
 evidence of new myocardial infarction or acute reduction in ejection 
fraction may suggest that pulmonary edema is not transfusion related </li></ul></li><li class="li"> further administration of blood products and other fluids should be discontinued or limited as much as possible </li></ul></li></ul></li> <li class="li"> see <eplink linkfield="AN" linkkey="T919220">Transfusion-associated lung disorders</eplink> for additional information </li> </ul> </section> </section> <section id="sec-Acute-noncardiogenic-pulmonary-edema"> <h4 id="Acute-noncardiogenic-pulmonary-edema" level="1">Acute noncardiogenic pulmonary edema</h4> <anchor name="Acute-noncardiogenic-pulmonary-edema"></anchor> <section id="sec-Acute-respiratory-distress-syndrome--ARDS"> <h4 id="Acute-respiratory-distress-syndrome--ARDS" level="2">Acute respiratory distress syndrome (ARDS)</h4> <anchor name="Acute-respiratory-distress-syndrome--ARDS"></anchor> <ul class="ul"> <li class="li">management of patients with acute respiratory distress syndrome (ARDS) <ul class="ul"><li class="li"> treatment is generally supportive in combination with aggressive management of precipitating conditions </li><li class="li"> mechanical ventilation <ul class="ul"><li class="li">
 mechanical ventilation can contribute to lung injury so goal should be 
to maintain adequate rather than "normal" gas exchange to minimize lung 
injury </li><li class="li"> optimal ventilator settings may require 
heavy sedation and even neuromuscular blockade if sedation and 
analgesics are not successful to ensure ventilation synchrony </li><li class="li"> standard ARDSNet protocol for mechanical ventilation for patients with ARDS <ul class="ul"><li class="li">
 set initial tidal volume to 8 mL/kg predicted body weight and reduce 
tidal volume by 1 mL/kg at ≤ 2-hour intervals until tidal volume is 6 
mL/kg predicted body weight </li><li class="li"> set initial respiratory rate to approximate baseline minute ventilation (≤ 35 breaths per minute) </li><li class="li"> adjust tidal volume (with goal ≤ 6 mL/kg predicted body weight) and respiratory rate to achieve both <ul class="ul"><li class="li"> plateau pressure goal of ≤ 30 cm H<sc><subs>2</subs></sc>O </li><li class="li"> pH goal of 7.3-7.45 </li></ul></li><li class="li"> oxygenation goal is PaO<sc><subs>2 </subs></sc> 55-80 mm Hg (SpO<sc><subs>2 </subs></sc> 88%-95%) </li><li class="li"> consider using incremental fraction of inspired oxygen (FiO<sc><subs>2</subs></sc>)/positive end expiratory pressure (PEEP) combinations to achieve oxygenation goal </li></ul></li><li class="li">
 American Thoracic Society/European Society of Intensive Care 
Medicine/Society of Critical Care Medicine (ATS/ESICM/SCCM) 2017 
recommendations on mechanical ventilation in adults with acute 
respiratory distress syndrome <ul class="ul"><li class="li"> limit tidal volume (4-8 mL/kg predicted body weight) and inspiratory pressure (plateau pressure &lt; 30 cm H<sc><subs>2</subs></sc>O) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ATSESICMSCCMGRADE">ATS/ESICM/SCCM Strong recommendation, Moderate confidence</a>) </li><li class="li"> avoid routine use of high-frequency oscillatory ventilation in patients with moderate or severe ARDS (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ATSESICMSCCMGRADE">ATS/ESICM/SCCM Strong recommendation, High confidence</a>) </li><li class="li"> consider higher rather than lower levels of positive end-expiratory pressure in patients with moderate or severe ARDS (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ATSESICMSCCMGRADE">ATS/ESICM/SCCM Conditional recommendation, Moderate confidence</a>) </li><li class="li"> use prone positioning for &gt; 12 hours per day in patients with severe ARDS (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ATSESICMSCCMGRADE">ATS/ESICM/SCCM Strong recommendation, Moderate-High confidence</a>) </li><li class="li"> consider recruitment maneuvers (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ATSESICMSCCMGRADE">ATS/ESICM/SCCM Conditional recommendation, Low-Moderate confidence</a>) </li><li class="li"> Reference - <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28459336?dopt=Abstract" target="%5Fblank"> Am J Respir Crit Care Med 2017 May 1;195(9):1253</a></li></ul></li></ul></li><li class="li"> general supportive measures <ul class="ul"><li class="li">
 conservative fluid management in patients with acute lung injury (ALI) 
improves fluid balance, reduces need for mechanical ventilation and 
shortens intensive care unit (ICU) stay (level 1 [likely reliable] 
evidence) </li><li class="li"> pulmonary artery catheters do not reduce 
mortality or length of stay for adult patients in ICU (level 1 [likely 
reliable] evidence) </li><li class="li"> venous thromboembolism prophylaxis suggested with low-molecular-weight heparin or low-dose unfractionated heparin (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCPGRADFEFORPI">ACCP Grade 2C</a>), or mechanical thromboprophylaxis if heparin contraindicated (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCPGRADFEFORPI">ACCP Grade 2C</a>) </li></ul></li><li class="li">
 referral for extracorporeal membrane oxygenation (ECMO) associated with
 improved survival compared to conventional ventilation support in 
patients with severe respiratory failure (level 2 [mid-level] evidence) </li><li class="li"> pharmacologic therapy <ul class="ul"><li class="li"> cisatracurium besylate (Nimbex) improves mortality in patients with severe ARDS (level 1 [likely reliable] evidence) </li><li class="li"> corticosteroids have conflicting evidence regarding effect on mortality in adults with ARDS <ul class="ul"><li class="li"> corticosteroids associated with <ul class="ul"><li class="li"> no significant difference in mortality in patients with unselected ARDS or sepsis-related ARDS </li><li class="li"> increased risk of mortality in patients with influenza related ARDS </li><li class="li"> decreased risk of mortality in patients with postoperative ARDS </li></ul></li><li class="li"> consider in early moderate to severe ARDS with partial pressure of oxygen in arterial blood (PaO<sc><subs>2</subs></sc>) to fraction of inspired oxygen (FiO<sc><subs>2</subs></sc>) of &lt; 200 and within 14 days (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--SCCM2017GRADE">SCCM/ESICM Conditional recommendation, Moderate quality of evidence</a>) </li></ul></li><li class="li">
 inhaled nitric oxide does not appear to reduce mortality and may 
increase risk of renal impairment (level 2 [mid-level] evidence) </li><li class="li"> no evidence to support use of aerosolized prostacyclin for patients with ARDS </li><li class="li"> surfactant <ul class="ul"><li class="li">
 exogenous surfactant (calfactant) in mechanical ventilation does not 
reduce mortality in adults with acute respiratory distress syndrome 
(level 1 [likely reliable] evidence) </li><li class="li"> inconsistent evidence for effect of exogenous surfactant (calfactant) on mortality in children </li></ul></li></ul></li><li class="li"> see <eplink linkfield="AN" linkkey="T113803">Acute respiratory distress syndrome (ARDS)</eplink> for additional information </li></ul></li> </ul> </section> <section id="sec-Negative-pressure-pulmonary-edema"> <h4 id="Negative-pressure-pulmonary-edema" level="2">Negative-pressure pulmonary edema</h4> <anchor name="Negative-pressure-pulmonary-edema"></anchor> <ul class="ul"> <li class="li"> patients with negative-pressure pulmonary edema<sc><sups>(<a class="link internal jump-link" href="#GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3105">3</a>)</sups></sc><ul class="ul"><li class="li"> typically managed with endotracheal intubation and positive pressure ventilation <ul class="ul"><li class="li"> if prolonged biting or obstruction of tube, consider sedation and/or paralysis </li><li class="li">
 if endotracheal intubation not possible (such as in patients with acute
 epiglottitis), consider airway access via cricothyrotomy or tracheotomy
 </li></ul></li><li class="li"> other treatments that may be considered (unless specifically contraindicated) <ul class="ul"><li class="li"> diuretic therapy </li><li class="li"> low tidal volume ventilation </li><li class="li"> beta agonists </li></ul></li><li class="li"> if severe, refractory hypoxemia, consider neuromuscular blockade, proning, or extracorporal membrane oxygenation </li></ul></li> </ul> </section> <section id="sec-High-altitude-pulmonary-edema--HAPE"> <h4 id="High-altitude-pulmonary-edema--HAPE" level="2">High-altitude pulmonary edema (HAPE)</h4> <anchor name="High-altitude-pulmonary-edema--HAPE"></anchor> <ul class="ul"> <li class="li"> management of patients with suspected HAPE <ul class="ul"><li class="li"> descent from altitude <ul class="ul"><li class="li"> if possible, descend until symptoms resolve (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--WMSGRADE">WMS Grade 1A</a>) </li><li class="li"> descending to 300-1,000 meters generally adequate but varies by individual </li><li class="li"> individuals should not descend alone </li></ul></li><li class="li"> if descent not possible, consider <ul class="ul"><li class="li"> supplemental oxygen (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--WMSGRADE">WMS Grade 1B</a> for HAPE) </li><li class="li"> portable hyperbaric chamber (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--WMSGRADE">WMS Grade 1B</a>) </li></ul></li><li class="li"> nifedipine sustained-release 30 mg orally 2 times daily (without a loading dose) as adjunct to descent or oxygen (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--WMSGRADE">WMS Grade 1C</a>) </li><li class="li"><anchor name="HIGH-ALTITUDE-PULMONARY-EDEMA--HAPE---ANC-1927338731" target-type="anchor"></anchor> insufficient evidence to evaluate efficacy of pharmacological and nonpharmacological treatments for altitude illnesses <ul class="ul"><li class="li"> based on Cochrane review </li><li class="li"> Reference - <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/29959871?dopt=Abstract" target="%5Fblank"> Cochrane Database Syst Rev 2018 Jun 30;6:CD009567</a></li></ul></li><li class="li"> see <eplink linkfield="AN" linkkey="T116210">Acute altitude illnesses</eplink> for additional information </li></ul></li> </ul> </section> <section id="sec-Neurogenic-pulmonary-edema"> <h4 id="Neurogenic-pulmonary-edema" level="2">Neurogenic pulmonary edema</h4> <anchor name="Neurogenic-pulmonary-edema"></anchor> <ul class="ul"> <li class="li"> management of patients with neurogenic pulmonary edema <ul class="ul"><li class="li">
 goals of management include supportive treatment for pulmonary edema 
with simultaneous management of underlying neurologic cause </li><li class="li">
 Neurocritical Care Society (NCS) recommends judicious use of diuretics 
to achieve euvolemia and avoidance of excessive fluid intake in patients
 with aneurysmal subarachnoid hemorrhage and pulmonary edema or other 
evidence of lung injury (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--NCSGRADE">NCS Strong recommendation, Moderate quality evidence</a>) </li><li class="li"> supportive treatment typically includes combination of volume management and mechanical ventilation <ul class="ul"><li class="li"> volume management <ul class="ul"><li class="li"> can be achieved with vasoactive drugs, diuretics, and/or fluid supplements </li><li class="li">
 appropriate volume management can be challenging due to need to balance
 fluid supplementation for brain resuscitation (perfusion) with volume 
reduction to control pulmonary edema </li></ul></li><li class="li"> goal of mechanical ventilation is combination of lung protective measures and measures to prevent hypoxemia and hypercapnia <ul class="ul"><li class="li"> use of low tidal volume ventilation for lung injury needs to be weighed against need for normocapnia to resolve brain injury </li><li class="li"> hyperventilation with partial pressure of carbon dioxide (PaCO<sc><subs>2</subs></sc>) goal of 32-34 mm Hg can be considered as short-term intervention to reduce intracranial pressure </li><li class="li">
 positive end-expiratory pressure (PEEP) can be considered to improve 
oxygenation, but effect of PEEP on brain uncertain (may also increase 
intracranial pressure and decrease cerebral perfusion pressure) </li></ul></li></ul></li><li class="li">
 treatment options reported to reduce intracranial pressure in patients 
with neurogenic pulmonary edema due to varying causes include <ul class="ul"><li class="li"> decompression and clot evacuation </li><li class="li"> osmotic diuretics </li><li class="li"> antiepileptics </li><li class="li"> tumor resection </li><li class="li"> corticosteroids </li></ul></li><li class="li"> corticosteroids <ul class="ul"><li class="li"> may be considered in certain neurologic conditions, such as brain tumors and multiple sclerosis </li><li class="li">
 may be contraindicated if use would exacerbate underlying neurologic 
condition (such as in patients with traumatic brain injury) </li></ul></li><li class="li"> therapies reported to resolve neurogenic pulmonary edema in case reports <ul class="ul"><li class="li">
 extracorporeal membrane oxygenation reported to resolve fulminant 
neurogenic pulmonary edema in case report of 28-year-old woman with 
ruptured intracranial aneurysm (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/23772167?dopt=Abstract" target="%5Fblank"> J Korean Med Sci 2013 Jun;28(6):962</a> <a class="link internal jump-link" href="https://jkms.org/DOIx.php?id=10.3346/jkms.2013.28.6.962" target="%5Fblank">full-text</a>) </li><li class="li">
 phentolamine IV reported to resolve neurogenic pulmonary edema in case 
report of 59-year-old man with ruptured arteriovenous malformation (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22396565?dopt=Abstract" target="%5Fblank"> Chest 2012 Mar;141(3):793</a>, commentary can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22948592?dopt=Abstract" target="%5Fblank"> Chest 2012 Sep;142(3):809</a> ) </li></ul></li></ul></li> <li class="li"> see <eplink linkfield="AN" linkkey="T922924">Neurogenic pulmonary edema</eplink> for additional information </li> </ul> </section> </section> <section id="sec-Chronic-pulmonary-edema"> <h4 id="Chronic-pulmonary-edema" level="1">Chronic pulmonary edema</h4> <anchor name="Chronic-pulmonary-edema"></anchor> <section id="sec-Heart-failure-with-reduced-ejection-fraction"> <h4 id="Heart-failure-with-reduced-ejection-fraction" level="2">Heart failure with reduced ejection fraction</h4> <anchor name="Heart-failure-with-reduced-ejection-fraction"></anchor> <ul class="ul"> <li class="li">management of patients with heart failure with reduced ejection fraction <ul class="ul"><li class="li"> recommended guideline-directed medical therapy for all patients with symptomatic heart failure with reduced ejection fraction <ul class="ul"><li class="li"> angiotensin-converting enzyme (ACE) inhibitors (or angiotensin receptor blockers [ARBs] if intolerant to ACE inhibitors) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level A</a>) <ul class="ul"><li class="li">
 ACE inhibitors appear to reduce mortality and rates of myocardial 
infarction and hospital admission in patients with left ventricular 
dysfunction or symptomatic heart failure (level 2 [mid-level] evidence) </li><li class="li">
 ARBs reduce heart failure hospitalization (level 1 [likely reliable] 
evidence) and possibly mortality (level 2 [mid-level] evidence) </li><li class="li">
 ARBs may have similar clinical outcomes compared with ACE inhibitors, 
but may be better tolerated (level 2 [mid-level] evidence) </li></ul></li><li class="li"> beta blockers (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level A</a>) <ul class="ul"><li class="li">
 beta blockers (bisoprolol, carvedilol, or sustained-release metoprolol 
succinate) reduce mortality in stable patients with class II and III 
heart failure (level 1 [likely reliable] evidence) and possibly class IV
 heart failure (level 2 [mid-level] evidence) </li></ul></li></ul></li><li class="li">
 recommended guideline-directed medical therapy for selected patients 
with symptomatic heart failure with reduced ejection fraction <ul class="ul"><li class="li"> loop diuretics for all volume overload, NYHA class II-IV patients (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level C</a>) <ul class="ul"><li class="li"> diuretics may reduce risk of death and worsening heart failure and improve exercise capacity (level 2 [mid-level] evidence) </li></ul></li><li class="li"> hydralazine plus isosorbide dinitrate for persistently symptomatic, NYHA class III-IV, self-identified black patients (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level A</a>)<ul class="ul"><li class="li">
 addition of isosorbide dinitrate plus hydralazine (BiDil) to standard 
heart failure therapy reduces mortality in black patients with advanced 
heart failure (level 1 [likely reliable] evidence) </li></ul></li><li class="li">
 aldosterone antagonist for NYHA class II-IV patients with serum 
creatinine &lt; 2.5 mg/dL (221 mcmol/L) in men or &lt; 2 mg/dL (177 
mcmol/L) in women and potassium &lt; 5 mEq/dL (5 mmol/L) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level A</a>) <ul class="ul"><li class="li"> monitor for hyperkalemia and impaired renal function </li><li class="li">
 aldosterone blockers (eplerenone [Inspra] or spironolactone [generic, 
Aldactone]) reduce all-cause mortality and hospitalizations in patients 
with left ventricular dysfunction and heart failure or postmyocardial 
infarction (level 1 [likely reliable] evidence), including patients with
 mild symptoms (level 1 [likely reliable] evidence) </li></ul></li><li class="li"> ivabradine <ul class="ul"><li class="li">
 consider in patients in sinus rhythm, ejection fraction ≤ 35%, 
persisting heart rate ≥ 70 beats/minute, and persisting symptoms (New 
York Heart Association [NYHA] class II-IV) despite treatment with 
standard therapy (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class IIa, Level B</a>) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACC-AHA-HFSAGRADE">ACC/AHA/HFSA Class IIa, Level B-R</a>) </li><li class="li">
 in patients with left ventricular ejection fraction ≤ 35% and heart 
rate ≥ 70 beats/minute, ivabradine reduces hospital admission rates for 
worsening heart failure (level 1 [likely reliable] evidence), but may 
not reduce all-cause or cardiovascular mortality </li><li class="li"> ivabradine may reduce risk of recurrent hospitalizations for worsening heart failure (level 2 [mid-level] evidence) </li></ul></li></ul></li><li class="li"> sacubitril/valsartan <ul class="ul"><li class="li">
 consider switching from ACE inhibitor or ARB to sacubitril/valsartan in
 patients with symptomatic heart failure, ejection fraction ≤ 35%, and 
elevated B-type natriuretic peptide (BNP) or N-terminal pro-BNP levels, 
but be aware of risk for symptomatic hypotension </li><li class="li"> 
replacement of angiotensin-converting enzyme (ACE) inhibitors or 
angiotensin receptor blockers (ARB) with angiotensin receptor–neprilysin
 inhibitor (ARNI) is recommended to further reduce morbidity and 
mortality for patients with chronic symptomatic (New York Heart 
Association class II or III) heart failure with reduced ejection 
fraction (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACC-AHA-HFSAGRADE">ACC/AHA/HFSA Class I, Level B-R</a>) </li><li class="li">
 sacubitril/valsartan recommended instead of ACE inhibitor or 
angiotensin receptor blocker (unless contraindicated) in patients with 
New York Heart Association class II-III heart failure and left 
ventricular ejection fraction ≤ 40% with ongoing symptoms of heart 
failure despite optimal treatment (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--SIGNGRADE">SIGN Strong recommendation</a>) </li><li class="li">
 sacubitril/valsartan recommended as replacement for ACE inhibitor to 
further reduce risk of death and heart failure hospitalization in 
ambulatory patients with heart failure with reduced ejection fraction 
and each of the following (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class I, Level B</a>) <ul class="ul"><li class="li"> symptomatic despite optimal treatment with an ACE inhibitor, beta blocker, and a mineralocorticoid receptor antagonist </li><li class="li">
 plasma BNP ≥ 150 pg/mL or plasma NT-proBNP ≥ 600 pg/mL, or if heart 
failure hospitalization within last 12 months, plasma BNP ≥ 100 pg/mL or
 plasma NT-proBNP ≥ 400 pg/mL </li><li class="li"> able to tolerate enalapril 10 mg orally twice daily </li></ul></li><li class="li">
 treatment with sacubitril/valsartan, beta blocker, and 
mineralocorticoid receptor antagonist reduces risk of sudden death and 
is recommended for patients with heart failure with reduced ejection 
fraction and ventricular arrhythmias (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class I, Level A</a>) </li><li class="li">
 sacubitril/valsartan may decrease mortality, heart failure 
hospitalization, and risk for worsening heart failure compared to 
enalapril in patients with symptomatic heart failure and ejection 
fraction ≤ 35%, but may increase risk for symptomatic hypotension (level
 2 [mid-level] evidence) </li><li class="li"> review of new class of drugs for systolic heart failure: the PARADIGM-HF study can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/26469827?dopt=Abstract" target="%5Fblank"> Cleve Clin J Med 2015 Oct;82(10):693</a></li></ul></li><li class="li">
 other medications that may be used in selected patients with heart 
failure include digoxin, trimetazidine, anticoagulants, statins, IV iron
 supplementation, amiodarone, n-3 polyunsaturated fatty acids, and 
coenzyme Q10 </li><li class="li"> measures to reduce hospitalization in patients at high risk of rehospitalization include <ul class="ul"><li class="li"> heart failure structured management and education <ul class="ul"><li class="li">
 comprehensive discharge planning with post discharge support reduces 
readmission rates in heart failure patients (level 1 [likely reliable] 
evidence) </li><li class="li"> interventions which may reduce mortality and hospitalizations include (level 2 [mid-level] evidence) <ul class="ul"><li class="li"> multidisciplinary disease management programs </li><li class="li"> N-terminal pro-B-type natriuretic peptide-guided intensive patient management </li><li class="li"> telephonic case management or support </li></ul></li><li class="li">
 multidisciplinary heart failure disease-management programs recommended
 to facilitate implementation of guideline-directed medical therapy and 
to address different barriers to behavioral change (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level B</a>) </li></ul></li><li class="li">
 exercise training may be safe in patients with heart failure and may 
reduce heart failure-related hospitalizations in patients with systolic 
heart failure (level 2 [mid-level] evidence) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level A</a>) </li><li class="li">
 wireless pulmonary artery pressure monitoring reduces heart 
failure-related hospitalizations in patients with NYHA Class III heart 
failure and previous heart failure hospitalization (level 1 [likely 
reliable] evidence) </li></ul></li><li class="li"> therapies that may be used in patients with medication-refractory heart failure or under specific circumstances include <ul class="ul"><li class="li"> implanted cardiac devices <ul class="ul"><li class="li"> implantable cardioverter-defibrillators (ICDs) may reduce risk of death in specific patient populations </li><li class="li">
 cardiac resynchronization therapy can be used in selected patients with
 medication refractory heart failure to improve cardiac function and 
treatment of heart failure </li><li class="li"> mechanical circulatory support may improve cardiac output in patients with heart failure refractory to medical management </li></ul></li><li class="li">
 cardiac transplantation - improvement in survival appears limited to 
patients with worst prognosis prior to surgery (level 2 [mid-level] 
evidence) </li></ul></li><li class="li"> sodium restriction not well 
supported by evidence, but considered reasonable for patients with 
symptomatic heart failure to reduce congestive symptoms (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIa, Level C</a>) </li><li class="li"> long-term follow-up should include monitoring of <ul class="ul"><li class="li"> serum electrolytes and renal function (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level C</a>) </li><li class="li"> volume status and supine/upright hypotension (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level B</a>) </li><li class="li"> measurement of ejection fraction and measurement of severity of structural remodeling in patients with (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level C</a>) <ul class="ul"><li class="li"> significant change in clinical status </li><li class="li"> clinical event (or recovery from clinical event) </li><li class="li"> treatment that may affect cardiac function </li><li class="li"> potential candidacy for device therapy<img src="Pulmonary%20Edema%20-%20Approach%20to%20the%20Patient_files/I506082.jpg" alt="I506082.jpg" title="Management of heart failure. : Stages in the development of heart failure and recommended therapy by stage. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin-receptor blocker; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; DM, diabetes mellitus; EF, ejection fraction; GDMT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HRQOL, health-related quality of life; HTN, hypertension; ICD, implantable cardioverter-defibrillator; LV, left ventricular; LVH, left ventricular hypertrophy; MCS, mechanical circulatory support; MI, myocardial infarction. Adapted from Hunt et al."></li></ul></li></ul></li></ul></li> <li class="li"> see <eplink linkfield="AN" linkkey="T114099">Heart failure with reduced ejection fraction</eplink> for additional information </li> </ul> </section> <section id="sec-Heart-failure-with-preserved-ejection-fraction"> <h4 id="Heart-failure-with-preserved-ejection-fraction" level="2">Heart failure with preserved ejection fraction</h4> <anchor name="Heart-failure-with-preserved-ejection-fraction"></anchor> <ul class="ul"> <li class="li">management of patients with heart failure with preserved ejection fraction <ul class="ul"><li class="li">
 initial management of patients with acute heart failure and preserved 
ejection fraction is tailored toward treatment of volume overload, while
 maintaining adequate filling pressures (so as not to over-diurese), and
 heart rate control </li><li class="li"> see <eplink linkfield="AN" linkkey="T114879">Acute heart failure</eplink> topic for additional information on emergency treatment </li><li class="li">
 patient education regarding diet, medications, activity and exercise, 
symptoms of worsening heart failure (seek medical attention if rapid 
weight gain in short period of time) </li><li class="li"> diuretics recommended for relief of symptoms due to volume overload (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level C</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHA2017GRADE">ACC/AHA Class I, Level C-EO</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class I, Level B</a>) </li><li class="li"> control systolic and diastolic hypertension (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level B</a>) <ul class="ul"><li class="li">
 beta blockers, ACE inhibitors, and angiotensin receptor blockers (ARBs)
 are reasonable choices for patients with hypertension and heart failure
 with preserved ejection fraction (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIa, Level C</a>) </li></ul></li><li class="li">
 perindopril might reduce unplanned heart failure related 
hospitalization rates in patients with diastolic dysfunction (level 2 
[mid-level] evidence) </li><li class="li"> angiotensin receptor blockers
 (ARBs) might reduce hospitalization for heart failure but not total 
hospitalizations or mortality in patients with symptomatic heart failure
 and ejection fraction &gt; 40% (level 2 [mid-level] evidence) </li><li class="li">
 consider aldosterone receptor antagonists to decrease hospitalizations 
in patients with ejection fraction ≥ 45%, elevated brain natriuretic 
peptide levels or heart failure admission within 1 year, estimated 
glomerular filtration rate &gt; 30 mL/minute, serum creatinine &lt; 2.5 
mg/dL, and potassium &lt; 5 mEq/L (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACC-AHA-HFSAGRADE">ACC/AHA/HFSA Class IIb, Level B-NR</a>) </li><li class="li">
 beta blockers may reduce mortality but may not affect heart failure 
hospitalization in patients with heart failure with preserved ejection 
fraction (level 2 [mid-level] evidence) </li><li class="li"> wireless 
pulmonary artery pressure monitoring reduces heart failure-related 
hospitalizations in patients with New York Heart Association (NYHA) 
Class III heart failure and previous heart failure hospitalization 
(level 1 [likely reliable] evidence) </li><li class="li"> coronary 
revascularization reasonable in patients with coronary artery disease in
 whom symptomatic or demonstrable myocardial ischemia is judged to have 
adverse effect on heart failure symptoms (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIa, Level C</a>) </li><li class="li"> additional evidence regarding drugs for heart failure with preserved ejection fraction is limited <ul class="ul"><li class="li">
 spironolactone may decrease risk of hospitalization for heart failure 
(but not cardiovascular mortality) in patients with heart failure with 
preserved ejection fraction (level 2 [mid-level] evidence) </li><li class="li">
 digoxin does not reduce morbidity or mortality in patients with heart 
failure with preserved ejection fraction and normal sinus rhythm (level 1
 [likely reliable] evidence) </li><li class="li"> sildenafil does not improve cardiovascular endurance (level 1 [likely reliable] evidence) </li><li class="li">
 isosorbide mononitrate titrated up to 120 mg orally daily over 2 weeks 
does not increase daily activity or improve quality of life in patients 
with heart failure with preserved ejection fraction (level 1 [likely 
reliable] evidence) </li></ul></li></ul></li> <li class="li"> see <eplink linkfield="AN" linkkey="T193266">Heart failure with preserved ejection fraction</eplink> for additional information </li> </ul> </section> <section id="sec-Hypertrophic-cardiomyopathy"> <h4 id="Hypertrophic-cardiomyopathy" level="2">Hypertrophic cardiomyopathy</h4> <anchor name="Hypertrophic-cardiomyopathy"></anchor> <ul class="ul"> <li class="li">management of patients with hypertrophic cardiomyopathy <ul class="ul"><li class="li"> for asymptomatic patients, treat comorbidities that might contribute to cardiovascular disease (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level C</a>) </li><li class="li"> activity <ul class="ul"><li class="li">
 low intensity aerobic exercise suggested as a component of a healthy 
lifestyle for patients with asymptomatic hypertrophic cardiomyopathy (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIa, Level C</a>) </li><li class="li"> participation in intense competitive sports is not recommended for patients with hypertrophic cardiomyopathy (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class III, Level C</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class I, Level C</a> ) </li><li class="li"> participation reasonable for (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIa, Level C</a>) <ul class="ul"><li class="li"> low intensity competitive sports such as golf and bowling </li><li class="li"> a range of recreational sporting activities such swimming laps, modest hiking, and skating </li></ul></li></ul></li><li class="li"> medications for symptom treatment of obstructive or nonobstructive disease <ul class="ul"><li class="li">
 beta blockers recommended to treat angina or dyspnea in adults, with 
caution in patients with sinus bradycardia or severe conduction disease (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level B</a>) </li><li class="li">
 in patients who do not respond to low doses of beta blockers for angina
 or dyspnea, titrate dose to resting heart rate &lt; 60-65 bpm and up to
 the generally accepted recommended maximum dose of the specific drug (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level B</a>) </li><li class="li">
 in patients who do not respond to beta blockers, have side effects, or 
contraindications, verapamil recommended to treat angina or dyspnea, (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level B</a>) <ul class="ul"><li class="li"> titrate from low doses up to 480 mg daily </li><li class="li"> use caution in patients with high outflow gradients, heart failure, sinus bradycardia </li></ul></li><li class="li"><eplink linkfield="AN" linkkey="T233313">diltiazem</eplink> may be considered for patients who do not tolerate verapamil or in whom verapamil is contraindicated (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIb, Level C</a>) </li><li class="li"> in children or adolescents, consider beta blockers to treat angina or dyspnea but monitor for side effects (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class IIb, Level C</a>) </li><li class="li">
 left ventricular apical aneurysms rarely require treatment, but if 
thrombi present within aneurysm, treatment usually includes long-term 
anticoagulation </li></ul></li><li class="li"> implantable cardioverter defibrillators (ICDs) <ul class="ul"><li class="li"> recommended for patients with a history of any of the following if meaningful survival &gt; 1 year expected <ul class="ul"><li class="li"> cardiac arrest (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class I, Level B</a> ) due to ventricular tachycardia or ventricular fibrillation (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACC-AHA-HFSAGRADE">AHA/ACC/HRS Class I, Level B-NR</a>) </li><li class="li"> ventricular fibrillation (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class I, Level B</a> ) </li><li class="li"> hemodynamically significant ventricular tachycardia (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE">ACCF/AHA Class I, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE">ESC Class I, Level B</a> ) </li><li class="li"> spontaneous sustained ventricular tachycardia causing syncope or hemodynamic compromise (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACC-AHA-HFSAGRADE">AHA/ACC/HRS Class I, Level B-NR</a>) </li></ul></li><li class="li">
 implantable cardioverter-defibrillators reported to terminate 
ventricular arrhythmias in patients with hypertrophic cardiomyopathy and
 high risk of sudden death (level 3 [lacking direct] evidence) <img src="Pulmonary%20Edema%20-%20Approach%20to%20the%20Patient_files/I506061.jpg" alt="I506061.jpg" title="Diagnosis and treatment of hypertrophic cardiomyopathy. : Treatment algorithm. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DM, diabetes mellitus; EF, ejection fraction; GL, guidelines; HCM, hypertrophic cardiomyopathy; HTN, hypertension; and LV, left ventricular."></li></ul></li></ul></li> <li class="li"> see <eplink linkfield="AN" linkkey="T115426">Hypertrophic cardiomyopathy</eplink> for additional information </li> </ul> </section> <section id="sec-Valvular-disease"> <h4 id="Valvular-disease" level="2">Valvular disease</h4> <anchor name="Valvular-disease"></anchor> <section id="sec-Mitral-stenosis"> <h4 id="Mitral-stenosis" level="3">Mitral stenosis</h4> <anchor name="Mitral-stenosis"></anchor> <ul class="ul"> <li class="li">management of patients with mitral stenosis<ul class="ul"><li class="li"> heart rate control <ul class="ul"><li class="li"> in mitral stenosis patients with atrial fibrillation, heart rate control may be beneficial if fast ventricular response (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level C</a>) </li><li class="li"> in mitral stenosis patients in normal sinus rhythm, consider beta blocker if symptoms during exercise (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIb, Level B</a>) </li></ul></li><li class="li"> in asymptomatic severe stenosis (stage C) <ul class="ul"><li class="li">percutaneous balloon valvuloplasty may be indicated for patients with <ul class="ul"><li class="li"> very severe stenosis (mitral valve area [MVA] ≤ 1 cm<sc><sups>2</sups></sc>) and favorable valve morphology without left atrial thrombus or severe mitral regurgitation (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level C</a>) </li><li class="li"> new onset atrial fibrillation who have favorable valve morphology without left atrial thrombus or severe mitral regurgitation (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIb, Level C</a>) </li><li class="li"> unfavorable characteristics and high risk of thromboembolism or hemodynamic compensation (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Level IIa, Level C</a>) </li></ul></li><li class="li">mitral valve surgery indicated if patient undergoing another cardiac surgery (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level C</a>) </li></ul></li><li class="li"> in symptomatic severe stenosis (stage D) <ul class="ul"><li class="li">percutaneous balloon valvuloplasty<ul class="ul"><li class="li">
 indicated for patients with favorable valve morphology without left 
atrial thrombus or moderate-to-severe mitral regurgitation (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level A</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level B</a>) </li><li class="li">
 may be indicated for patients with severe symptoms (New York Heart 
Association [NYHA] class III-IV) with severe mitral stenosis (MVA ≤ 1.5 
cm<sc><sups>2</sups></sc>, stage D) who have a suboptimal valve anatomy and who are not candidates for or at high risk for surgery (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIb, Level C</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level C</a>) </li></ul></li><li class="li">mitral valve surgery indicated for patients with <ul class="ul"><li class="li"> another indication for cardiac surgery (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level C</a>) </li><li class="li"> NYHA Class III-IV who are not high risk for surgery and not candidate for or have failed prior balloon commissurotomy (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>) </li></ul></li><li class="li">
 mitral valve surgery may also be indicated for patients with recurrent 
embolic events while receiving adequate anticoagulation, with surgery to
 include excision of the left atrial appendage (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIb, Level C</a>) </li></ul></li></ul></li> <li class="li">see <eplink linkfield="AN" linkkey="T115920">Mitral Stenosis</eplink> for additional information</li> </ul> </section> <section id="sec-Mitral-regurgitation"> <h4 id="Mitral-regurgitation" level="3">Mitral regurgitation</h4> <anchor name="Mitral-regurgitation"></anchor> <ul class="ul"> <li class="li">management of patients with mitral regurgitation<ul class="ul"><li class="li"> mitral valve surgery for mitral regurgitation is defined as either mitral valve replacement or repair</li><li class="li"> patients with acute severe mitral regurgitation <ul class="ul"><li class="li"> urgent surgery often indicated after stabilization of hemodynamic status </li><li class="li"> usual intervention is valve replacement</li><li class="li">medications such as positive inotropes, vasodilators, and diuretics may be used acutely for symptom control </li><li class="li">mechanical support (for example, with intra-aortic balloon pump) may be used prior to or during valve replacement</li></ul></li><li class="li"> patients with chronic primary (degenerative) mitral regurgitation <ul class="ul"><li class="li">medical therapy<ul class="ul"><li class="li">
 medical therapy may be considered if symptomatic (stage D) and left 
ventricular ejection fraction &lt; 60% if surgery not contemplated </li><li class="li">
 vasodilator therapy not indicated if normotensive and asymptomatic 
(stages B and C1) with normal left ventricular systolic function </li></ul></li><li class="li"> mitral valve surgery<ul class="ul"><li class="li"> recommended in the following patients <ul class="ul"><li class="li">
 asymptomatic (stage C2) mitral regurgitation and left ventricular 
ejection fraction ≤ 60% and/or left ventricular end-systolic diameter 
(LVESD) ≥ 40 mm (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>), or LVESD ≥ 45 mm (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level C</a>) </li><li class="li"> severe mitral regurgitation if undergoing cardiac surgery for other indications (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>) </li><li class="li"> symptomatic (stage D) mitral regurgitation and left ventricular ejection fraction &gt; 30% (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>), with left ventricular end-systolic diameter &lt; 55 mm (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level B</a>) </li></ul></li><li class="li"> may be considered in the following patients <ul class="ul"><li class="li">
 asymptomatic (stage C1) mitral regurgitation and preserved left 
ventricular (LV) function (LV ejection fraction &gt; 60% and LVSED &lt; 
40 mm) with progressive increase in left ventricular size or decrease in
 ejection fraction on serial imaging (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHA2017GRADE">AHA/ACC Class IIa, Level C-LD</a>) </li><li class="li"> asymptomatic mitral regurgitation with preserved left ventricular function and either (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) <ul class="ul"><li class="li"> new onset atrial fibrillation </li><li class="li"> resting pulmonary hypertension (systolic pulmonary pressure &gt; 50 mm Hg) </li></ul></li><li class="li"> asymptomatic mitral regurgitation with preserved left ventricular function if all of (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) <ul class="ul"><li class="li"> high likelihood of durable repair </li><li class="li"> flail leaflet </li><li class="li"> low surgical risk </li><li class="li"> left ventricular end-systolic diameter ≥ 40 mm </li></ul></li><li class="li">
 asymptomatic mitral regurgitation with preserved left-ventricular 
function, low surgical risk, high likelihood of durable repair, and 
either (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIb, Level C</a>) <ul class="ul"><li class="li"> pulmonary hypertension on exercise (systolic pulmonary artery pressure ≥ 60 mm Hg during exercise) </li><li class="li"> left atrial dilation (volume index ≥ 60 mL/m<sc><sups>2</sups></sc> body surface area [BSA]) and sinus rhythm </li></ul></li><li class="li">
 severe left ventricular dysfunction present defined as left ventricular
 ejection fraction &lt; 30% and/or left ventricular end-systolic 
diameter &gt; 55 mm and both (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) <ul class="ul"><li class="li"> refractory to medical therapy </li><li class="li"> high likelihood of durable repair and low comorbidity </li></ul></li><li class="li">
 severe left ventricular dysfunction present defined as left ventricular
 ejection fraction &lt; 30% and/or left ventricular end-systolic 
diameter &gt; 55 mm and both (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIb, Level C</a>) <ul class="ul"><li class="li"> refractory to medical therapy </li><li class="li"> low likelihood of durable repair and low comorbidity </li></ul></li><li class="li"> symptomatic severe (stage D) mitral regurgitation and left ventricular ejection fraction ≤ 30% (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIb, Level C</a>) </li></ul></li></ul></li><li class="li">mitral valve repair is recommended <ul class="ul"><li class="li">
 as preferred technique when result of repair expected to be durable in 
patients with severe primary (degenerative) mitral regurgitation (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level C</a>) </li><li class="li">
 over mitral valve replacement in patients with chronic severe primary 
(degenerative) mitral regurgitation requiring surgical treatment to 
either (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>) <ul class="ul"><li class="li"> posterior leaflet alone </li><li class="li"> anterior or both leaflets when result of repair expected to be successful and durable </li></ul></li><li class="li"> may be considered in the following patients <ul class="ul"><li class="li">
 asymptomatic severe (stage C1) mitral regurgitation and left 
ventricular ejection fraction &gt; 60% and left ventricular end-systolic
 diameter &lt; 40 mm if either <ul class="ul"><li class="li"> nonrheumatic disease present and repair likely to be successful and durable in patients with either of the following (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level B</a>) <ul class="ul"><li class="li"> new-onset atrial fibrillation </li><li class="li"> resting pulmonary hypertension (pulmonary artery systolic arterial pressure &gt; 50 mm Hg) </li></ul></li><li class="li"> both of the following are present (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level B</a>) <ul class="ul"><li class="li"> &gt; 95% chance that repair likely to be successful and durable without residual mitral regurgitation </li><li class="li"> expected mortality &lt; 1% when performed at Heart Valve Center of Excellence </li></ul></li></ul></li><li class="li"> asymptomatic moderate (stage B) mitral regurgitation when having cardiac surgery for other indications (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level C</a>) </li></ul></li></ul></li><li class="li">
 transcatheter mitral valve repair may be considered for severely 
symptomatic (New York Heart Association class III to IV) patients with 
severe (stage D) mitral regurgitation with favorable anatomy for repair 
procedure and both (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIb, Level B</a>)<ul class="ul"><li class="li"> reasonable life expectancy </li><li class="li">
 prohibitive surgical risk due to severe comorbid conditions with 
symptoms despite optimal guideline-directed medical therapy for heart 
failure </li></ul></li><li class="li"> mitral valve replacement should 
not be performed for treatment of isolated severe mitral regurgitation 
limited to &lt; 50% of posterior leaflet unless mitral valve repair 
attempted and was unsuccessful (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class III, Level B</a>)</li></ul></li><li class="li"> patients with chronic secondary (functional) mitral regurgitation <ul class="ul"><li class="li">
 guideline-directed medical therapy for heart failure including ACE 
inhibitors, angiotensin-receptor blockers, beta blockers, and/or 
aldosterone antagonists recommended for stages B to D mitral 
regurgitation if heart failure and reduced left ventricular ejection 
fraction present (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level A</a>) </li><li class="li">cardiac
 resynchronization therapy with biventricular pacing recommended for 
patients with symptomatic chronic severe secondary mitral regurgitation 
(stages B to D) who meet indications for device therapy use </li><li class="li"> mitral valve surgery<ul class="ul"><li class="li"> recommended if severe mitral regurgitation (defined as effective regurgitant orifice area ≥ 20 mm<sc><sups>2</sups></sc>
 and regurgitant volume &gt; 30 mL) and left ventricular ejection 
fraction &gt; 30% if having coronary artery bypass graft procedure (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level C</a>) </li><li class="li"> may be considered in the following patients <ul class="ul"><li class="li"> moderate mitral regurgitation if having coronary artery bypass graft procedure (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) </li><li class="li"> severe (stages C and D) mitral regurgitation if having coronary artery bypass graft or aortic valve replacement procedure (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level C</a>) </li><li class="li"> symptomatic severe mitral regurgitation and left ventricular ejection fraction &lt; 30%, if both (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) <ul class="ul"><li class="li"> option for revascularization </li><li class="li"> evidence of viability </li></ul></li><li class="li">
 severely symptomatic (New York Heart Association class III to IV) with 
severe (stage D) mitral regurgitation and persistent symptoms despite 
optimal guideline-directed medical therapy for heart failure (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIb, Level B</a>) </li><li class="li"> severe mitral regurgitation and left ventricular ejection fraction &gt; 30% if all of (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIb, Level C</a>) <ul class="ul"><li class="li"> symptomatic despite optimal medical management (including cardiac resynchronization if indicated) </li><li class="li"> revascularization not indicated </li><li class="li"> low comorbidities </li></ul></li></ul></li></ul></li><li class="li">mitral valve repair may be considered in patients with moderate mitral regurgitation (stage B) if having other cardiac surgery (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIb, Level C</a>) </li></ul></li></ul></li> <li class="li">see <eplink linkfield="AN" linkkey="T115306">Mitral Regurgitation</eplink> for additional information</li> </ul> </section> <section id="sec-Aortic-stenosis"> <h4 id="Aortic-stenosis" level="3">Aortic stenosis</h4> <anchor name="Aortic-stenosis"></anchor> <ul class="ul"> <li class="li">management of patients with aortic stenosis<ul class="ul"><li class="li"> in asymptomatic severe aortic stenosis (stage C) <ul class="ul"><li class="li"> no medical therapy proven to reduce progression, but echocardiography monitoring suggested (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level C</a>) </li><li class="li">aortic valve replacement (AVR) may be indicated for <ul class="ul"><li class="li"> left ventricular ejection fraction (LVEF) &lt; 50% (stage C2) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level C</a>) </li><li class="li"> having cardiac surgery for other indications (stage C or D) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level C</a>) </li><li class="li"> asymptomatic patients with very severe aortic stenosis (stage C1) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) </li><li class="li">
 apparently asymptomatic patients with severe aortic stenosis (stage C1)
 and decreased exercise tolerance or fall in systolic blood pressure on 
exercise testing (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) </li></ul></li></ul></li><li class="li"> in symptomatic severe aortic stenosis (stage D) <ul class="ul"><li class="li">AVR indicated for patients with severe aortic stenosis if symptoms (stage D1) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level B</a>) </li><li class="li"> AVR may be considered for symptomatic patients with low-flow/low-gradient severe aortic stenosis if either <ul class="ul"><li class="li"> reduced LVEF and severe aortic stenosis on low-dose dobutamine infusion (stage D2) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) </li><li class="li"> normal LVEF (stage D3) but with evidence that valve obstruction is most likely cause of symptoms (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level C</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) </li></ul></li><li class="li">
 percutaneous aortic balloon valvuloplasty may be considered in patients
 with symptomatic severe aortic stenosis as a bridge to AVR (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIb, Level C</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIb, Level C</a>) or as a palliative measure </li></ul></li><li class="li">AVR may improve survival in asymptomatic and symptomatic patients with severe aortic stenosis (level 2 [mid-level] evidence) <ul class="ul"><li class="li">
 AVR may be surgical AVR [SAVR] or transcatheter aortic valve 
implantation (TAVI) (also called transcatheter aortic valve replacement 
[TAVR]) <ul class="ul"><li class="li"> guidelines vary on the use of surgical AVR versus TAVI for patients with low to intermediate surgical risk: <ul class="ul"><li class="li">American Heart Association for surgical AVR versus TAVR <ul class="ul"><li class="li"> surgical AVR recommended when AVR indicated if low or intermediate surgical risk (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHA2017GRADE">AHA/ACC Class I, Level B-NR</a> ) </li><li class="li">
 surgical AVR or TAVR recommended for symptomatic patients with severe 
aortic stenosis (stage D) and high risk for surgical AVR (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHA2017GRADE">AHA/ACC Class I, Level A</a>) </li></ul></li><li class="li">
 BMJ Rapid Recommendations for TAVI versus SAVR for patients with severe
 symptomatic aortic stenosis at low to intermediate perioperative risk <ul class="ul"><li class="li"> transfemoral TAVI recommended rather than SAVR in patients aged 85 and older eligible for TAVI or SAVR (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--GRADE2008GRADE">GRADE Strong recommendation</a>)</li><li class="li"> transfemoral TAVI suggested rather than SAVR in patients aged 75 to &lt; 85 eligible for TAVI or SAVR (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--GRADE2008GRADE">GRADE Weak recommendation</a>)</li><li class="li"> SAVR suggested rather than transfemoral TAVI in patients aged 65 to &lt; 75 eligible for TAVI or SAVR (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--GRADE2008GRADE">GRADE Weak recommendation</a>)</li><li class="li"> SAVR recommended rather than transfemoral TAVI in patients &lt; 65 years old and eligible for TAVI or SAVR (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--GRADE2008GRADE">GRADE Strong recommendation</a>)</li><li class="li"> Reference - <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27680583?dopt=Abstract" target="%5Fblank"> BMJ 2016 Sep 28;354:i5085</a>; <a class="link internal jump-link" href="https://www.bmj.com/content/354/bmj.i5085.long" target="%5Fblank">full text</a>, full details at <a class="link internal jump-link" href="https://www.magicapp.org/app#/guideline/1308" target="%5Fblank">MAGICapp 2016 Oct 1</a></li></ul></li></ul></li></ul><ul class="ul"><li class="li">TAVI recommended in patients with prohibitive surgical risk and predicted post-TAVR survival &gt; 12 months (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level B</a>) </li><li class="li">transfemoral
 TAVI may reduce 2-year mortality compared to surgical aortic valve 
replacement in patients with severe aortic stenosis at low or 
intermediate risk of perioperative death (level 2 [mid-level] evidence) </li><li class="li">
 in patients with intermediate-risk severe aortic stenosis, TAVI and 
surgical AVR associated with similar risk of death or disabling stroke 
at 2 years, but TAVR associated with lower risk of serious bleeding and 
new atrial fibrillation (level 2 [mid-level] evidence) </li><li class="li">
 TAVI with SAPIEN 3 valve may decrease risk of death and stroke compared
 to surgical aortic valve replacement in patients with intermediate-risk
 severe aortic stenosis (level 2 [mid-level] evidence) </li><li class="li">
 in patients with severe aortic stenosis and heart failure symptoms, 
TAVI with self-expanding bioprosthesis appears at least effective as 
surgical AVR for 1-year mortality (level 2 [mid-level] evidence) </li><li class="li">
 in patients not suitable for conventional surgery TAVI may reduce 
2-year mortality, rehospitalization, and cardiac symptoms but increase 
risk of stroke, major bleeding, and other vascular complications (level 2
 [mid-level] evidence) </li></ul></li></ul><ul class="ul"><li class="li"> in patients having surgical AVR <ul class="ul"><li class="li">mechanical
 valve appears to have lower reoperation rate than bioprosthetic valve 
for aortic valve replacement (level 2 [mid-level] evidence), but 
associated with greater need for anticoagulation <ul class="ul"><li class="li"> bioprosthesis recommended if anticoagulant therapy is contraindicated or not desired (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level C</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level C</a>) and reasonable in patients &gt; 65-70 years old (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) </li><li class="li"> mechanical prosthesis reasonable for patients &lt; 60 years old without contraindication to anticoagulation (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) </li><li class="li"> mechanical valve or bioprosthesis reasonable in patients aged 60-70 years (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level B</a>) </li></ul></li><li class="li">limited
 sternotomy and standard median sternotomy for aortic valve replacement 
associated with similar in-hospital and 30-day mortality, but limited 
sternotomy may reduce duration of intensive care and hospitalization 
(level 2 [mid-level] evidence) </li></ul></li></ul></li><li class="li"> medical therapy has limited direct role in treatment of aortic stenosis <ul class="ul"><li class="li">hypertension may be treated with low starting doses, gradual titration, and frequent clinical monitoring (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>) </li><li class="li">vasodilators may be used with invasive hemodynamic monitoring for decompensated heart failure (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIb, Level C</a>) </li><li class="li">statins
 do not appear to reduce mortality or need for aortic valve surgery 
(level 2 [mid-level] evidence) and are not associated with slower 
progression of aortic stenosis (level 3 [lacking direct] evidence) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class III No Benefit, Level A</a>) </li></ul></li></ul></li> <li class="li">see <eplink linkfield="AN" linkkey="T114195">Aortic Stenosis</eplink> for additional information</li> </ul> </section> <section id="sec-Aortic-regurgitation"> <h4 id="Aortic-regurgitation" level="3">Aortic regurgitation</h4> <anchor name="Aortic-regurgitation"></anchor> <ul class="ul"> <li class="li">
 in asymptomatic mild to moderate aortic regurgitation (stage B), 
monitoring with periodic echocardiography may detect progression to 
severe aortic regurgitation </li> <li class="li"> in asymptomatic severe aortic regurgitation (stage C) <ul class="ul"><li class="li">medications do not have a clearly established role in asymptomatic aortic regurgitation </li><li class="li">aortic valve replacement (AVR)<ul class="ul"><li class="li"> recommended if <ul class="ul"><li class="li">
 left ventricular systolic dysfunction (ejection fraction &lt; 50%) at 
rest (stage C2) when systolic dysfunction not due to another cause (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level B</a>) </li><li class="li"> having cardiac surgery for other reason (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level C</a>), specifically surgery of ascending aorta or another valve (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level C</a>); AVR should also be considered if having cardiac surgery in patients with moderate aortic regurgitation (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level C</a>) </li></ul></li><li class="li"> should be considered if severe left ventricular dilation, specifically either <ul class="ul"><li class="li"> left ventricular end-systolic diameter [LVESD] &gt; 50 mm or LVESD &gt; 25 mm/m<sc><sups>2</sups></sc> body surface area (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) </li><li class="li"> left ventricular end-diastolic diameter &gt; 70 mm (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class IIa, Level C</a>) </li></ul></li><li class="li">
 may be considered for asymptomatic patients with normal left 
ventricular systolic function at rest (ejection fraction ≥ 50%, stage 
C1) with progressive severe left ventricular dilation (left ventricular 
end-diastolic diameter &gt; 65 mm) if low surgical risk (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIb, Level C</a>) </li></ul></li></ul></li> <li class="li"> in symptomatic severe aortic regurgitation (stage D) <ul class="ul"><li class="li">AVR
 recommended for patients with symptomatic severe aortic regurgitation 
regardless of left ventricular systolic function (stage D) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>; <a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level B</a>) </li><li class="li">ACE inhibitor or angiotensin-receptor blocker (ARB), and beta blocker, may be considered if surgery contraindicated (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class IIa, Level B</a>) </li><li class="li"> short-term vasodilators and inotropic agents may be used to bridge patients with severe heart failure awaiting valve surgery </li></ul></li> <li class="li">
 aortic valve repair may be an alternative to AVR in suitable patients 
with dilated annulus, cusp perforation, cusp prolapse, or cusp 
restriction </li> <li class="li"> aortic root replacement <ul class="ul"><li class="li"> recommended for patients with Marfan syndrome and aortic root disease (maximal ascending aortic diameter ≥ 50 mm) (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE">ESC/EACTS Class I, Level C</a>) </li><li class="li"> recommended for asymptomatic patients with bicuspid aortic valve if aortic root or ascending aorta diameter ≥ 55 mm (<a class="link internal jump-link" href="#GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE">AHA/ACC Class I, Level B</a>)</li><li class="li"> may be considered for other patients with aortic root disease if certain criteria are met </li></ul></li> <li class="li">
 transcatheter aortic valve intervention/repair (TAVI/TAVR) may be 
considered as off-label procedure in carefully selected patients with 
aortic regurgitation who are not candidates for standard aortic valve 
replacement </li> <li class="li">see <eplink linkfield="AN" linkkey="T113982">Aortic Regurgitation</eplink> for additional information</li> </ul> </section> </section> </section> </section> </section> <section id="sec-Guidelines-and-Resources" collapsible="true" bullettype="arrow"> <h2 id="Guidelines-and-Resources">Guidelines and Resources</h2> <anchor name="Guidelines-and-Resources"></anchor> <section id="sec-Guidelines"> <h3 id="Guidelines">Guidelines</h3> <anchor name="Guidelines"></anchor> <section id="sec-International-guidelines"> <h4 id="International-guidelines" level="1">International guidelines</h4> <anchor name="International-guidelines"></anchor> <ul class="ul"> <li class="li">
 American College of Chest Physicians/La Société de Réanimation de 
Langue Française (ACCP/SRLF) statement on competence in critical care 
ultrasonography can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/19188546?dopt=Abstract" target="%5Fblank"> Chest 2009 Apr;135(4):1050</a></li> <li class="li">
 American Thoracic Society/European Society of Intensive Care 
Medicine/Society of Critical Care Medicine (ATS/ESICM/SCCM) clinical 
practice guideline on mechanical ventilation in adult patients with 
acute respiratory distress syndrome can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28459336?dopt=Abstract" target="%5Fblank"> Am J Respir Crit Care Med 2017 May 1;195(9):1253</a>, correction can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28569586?dopt=Abstract" target="%5Fblank"> Am J Respir Crit Care Med 2017 Jun 1;195(11):1540</a>, commentary can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28932514?dopt=Abstract" target="%5Fblank"> J Thorac Dis 2017 Aug;9(8):2238</a></li> </ul> </section> <section id="sec-United-States-guidelines"> <h4 id="United-States-guidelines" level="1">United States guidelines</h4> <anchor name="United-States-guidelines"></anchor> <ul class="ul"> <li class="li"> American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA) <ul class="ul"><li class="li"> ACC/AHA/HFSA focused update of clinical practice guideline on management of heart failure can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28461259?dopt=Abstract" target="%5Fblank"> J Card Fail 2017 Aug;23(8):628</a>, <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28461007?dopt=Abstract" target="%5Fblank"> J Am Coll Cardiol 2017 Aug 8;70(6):776</a> <a class="link internal jump-link" href="http://www.onlinejacc.org/content/70/6/776?%5Fga=2.243160834.1216340351.1517249532-1087571939.1515620869" target="%5Fblank">full-text</a>, or <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28455343?dopt=Abstract" target="%5Fblank"> Circulation 2017 Aug 8;136(6):e137</a></li><li class="li"> ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27208050?dopt=Abstract" target="%5Fblank"> Circulation 2016 Sep 27;134(13):e282</a>, correction can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27672202?dopt=Abstract" target="%5Fblank"> Circulation 2016 Sep 27;134(13):e298</a></li></ul></li> <li class="li">
 American College of Cardiology Foundation/American Heart Association 
(ACCF/AHA) clinical practice guideline on management of heart failure 
can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/23741058?dopt=Abstract" target="%5Fblank"> Circulation 2013 Oct 15;128(16):e240</a></li> </ul> <ulist id="UNITED-STATES-GUIDELINES--SNIPPET-POINTER-1239938357"> <li class="li">American
 College of Chest Physicians (ACCP) Evidence-Based Clinical Practice 
Guidelines on Antithrombotic Therapy and Prevention of Thrombosis (Ninth
 Edition) recommendations on prevention of venous thromboembolism in 
nonsurgical patients can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22315261?dopt=Abstract" target="%5Fblank"> Chest 2012 Feb;141(2 Suppl):e195S</a> <a class="link internal jump-link" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278052/" target="%5Fblank">full-text</a>, commentary can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22796860?dopt=Abstract" target="%5Fblank"> Chest 2012 Jul;142(1):265</a> <a class="link internal jump-link" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418862/" target="%5Fblank">full-text</a></li>  <ul class="ul"> <li class="li"> AABB clinical practice guideline on red blood cell transfusion can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22751760?dopt=Abstract" target="%5Fblank"> Ann Intern Med 2012 Jul 3;157(1):49</a></li> <li class="li"> Wilderness Medical Society (WMS) 2014 practice guideline on prevention and treatment of acute altitude illness can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/25498261?dopt=Abstract" target="%5Fblank"> Wilderness Environ Med 2014 Dec;25(4 Suppl):S4</a></li> </ul> </ulist></section> <section id="sec-European-guidelines"> <h4 id="European-guidelines" level="1">European guidelines</h4> <anchor name="European-guidelines"></anchor> <ul class="ul"> <li class="li">
 European Society of Intensive Care Medicine (ESICM) consensus statement
 on circulatory shock and hemodynamic monitoring can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/25392034?dopt=Abstract" target="%5Fblank"> Intensive Care Med 2014 Dec;40(12):1795</a> <a class="link internal jump-link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239778/" target="%5Fblank">full-text</a></li> <li class="li"> European Society of Cardiology (ESC) guideline on diagnosis and treatment of acute and chronic heart failure can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27206819?dopt=Abstract" target="%5Fblank"> Eur Heart J 2016 Jul 14;37(27):2129</a> <a class="link internal jump-link" href="https://academic.oup.com/eurheartj/article/37/27/2129/1748921" target="%5Fblank">full-text</a>, correction can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28039335?dopt=Abstract" target="%5Fblank"> Eur Heart J 2018 Mar 7;39(10):860</a></li> <li class="li">
 Scottish Intercollegiate Guidelines Network (SIGN) national clinical 
guideline on management of chronic heart failure can be found in <a class="link internal jump-link" href="https://www.sign.ac.uk/assets/sign147.pdf" target="%5Fblank">SIGN 2016 Mar PDF</a></li> </ul> </section> <section id="sec-Central-and-South-American-guidelines"> <h4 id="Central-and-South-American-guidelines" level="1">Central and South American guidelines</h4> <anchor name="Central-and-South-American-guidelines"></anchor> <ul class="ul"> <li class="li"> Sociedade Brasileira de Cardiologia (SBC) <ul class="ul"><li class="li"> SBC summary of Brazilian guideline update on acute heart failure can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22858653?dopt=Abstract" target="%5Fblank"> Arq Bras Cardiol 2012 May;98(5):375</a> <a class="link internal jump-link" href="http://www.scielo.br/scielo.php?script=sci%5Farttext&amp;pid=S0066-782X2012000500001&amp;lng=en&amp;nrm=iso&amp;tlng=pt" target="%5Fblank">full-text</a> [English, Portuguese] </li><li class="li"> SBC Brazilian guideline on acute cardiac insufficiency can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/20721452?dopt=Abstract" target="%5Fblank"> Arq Bras Cardiol 2009;93(3 Suppl 3):2</a> <a class="link internal jump-link" href="http://www.scielo.br/scielo.php?script=sci%5Farttext&amp;pid=S0066-782X2009001900001&amp;lng=en&amp;nrm=iso&amp;tlng=pt" target="%5Fblank">full-text</a> [Portuguese] </li></ul></li> </ul> </section> <section id="sec-Australian-and-New-Zealand-guidelines"> <h4 id="Australian-and-New-Zealand-guidelines" level="1">Australian and New Zealand guidelines</h4> <anchor name="Australian-and-New-Zealand-guidelines"></anchor> <ul class="ul"> <li class="li">
 Queensland Ambulance Service (QAS) Clinical and Patient Safety Unit 
clinical practice guideline on respiratory/acute pulmonary oedema can be
 found at <a class="link internal jump-link" href="https://www.ambulance.qld.gov.au/docs/clinical/cpg/CPG%5FAcute%20pulmonary%20oedema.pdf" target="%5Fblank">QAS 2017 PDF</a></li> </ul> </section> </section> <section id="sec-Review-articles"> <h3 id="Review-articles">Review articles</h3> <anchor name="Review-articles"></anchor> <ul class="ul"> <li class="li"> review of pathophysiology and diagnosis of pulmonary edema can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/21219673?dopt=Abstract" target="%5Fblank"> Int J Tuberc Lung Dis 2011 Feb;15(2):155</a>, commentary can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/21740685?dopt=Abstract" target="%5Fblank"> Int J Tuberc Lung Dis 2011 Aug;15(8):1135</a></li> <li class="li"> <anchor name="REVIEW-ARTICLES--ANC-2067545623" target-type="anchor"></anchor> review of assessment of pulmonary edema can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/29174750?dopt=Abstract" target="%5Fblank"> J Cardiothorac Vasc Anesth 2018 Apr;32(2):901</a></li> <li class="li"> review of pulmonary edema and hypoxic respiratory failure can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27490597?dopt=Abstract" target="%5Fblank"> Pediatr Crit Care Med 2016 Aug;17(8 Suppl 1):S178</a></li> <li class="li"> review of negative pressure pulmonary edema can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27063348?dopt=Abstract" target="%5Fblank"> Chest 2016 Oct;150(4):927</a></li> <li class="li"> review of postobstructive pulmonary edema can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/20413250?dopt=Abstract" target="%5Fblank"> J Crit Care 2010 Sep;25(3):508.e1</a></li> <li class="li"> review of flash pulmonary edema can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/19917337?dopt=Abstract" target="%5Fblank"> Prog Cardiovasc Dis 2009 Nov-Dec;52(3):249</a></li> <li class="li"> review of environment-induced pulmonary edema can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28238713?dopt=Abstract" target="%5Fblank"> Lancet Respir Med 2017 May;5(5):374</a></li> <li class="li"> review of acute pulmonary edema can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/16382065?dopt=Abstract" target="%5Fblank"> N Engl J Med 2005 Dec 29;353(26):2788</a></li> <li class="li"> review of causes and treatment of edema in heart failure can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/23319101?dopt=Abstract" target="%5Fblank"> Nat Rev Cardiol 2013 Mar;10(3):156</a></li> <li class="li"> review of pathogenesis of high-altitude pulmonary edema can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/20417341?dopt=Abstract" target="%5Fblank"> Prog Cardiovasc Dis 2010 May-Jun;52(6):485</a></li> <li class="li"> review of opiates in treatment of acute cardiogenic pulmonary edema can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/18973635?dopt=Abstract" target="%5Fblank"> Emerg Med Australas 2008 Oct;20(5):384</a>,editorial can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/18973633?dopt=Abstract" target="%5Fblank"> Emerg Med Australas 2008 Oct;20(5):379</a>, commentary can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/19422415?dopt=Abstract" target="%5Fblank"> Emerg Med Australas 2009 Apr;21(2):160</a></li> <li class="li"> review of role of endothelial glycocalyx in pulmonary edema and acute lung injury can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/23835455?dopt=Abstract" target="%5Fblank"> Anesth Analg 2013 Sep;117(3):664</a> <a class="link internal jump-link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790575/" target="%5Fblank">full-text</a></li> <li class="li"> review of role of transpulmonary thermodilution in assessment of lung water and pulmonary edema can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28465120?dopt=Abstract" target="%5Fblank"> J Cardiothorac Vasc Anesth 2017 Aug;31(4):1471</a></li> <li class="li"> review of arterial pressure variation and goal-directed fluid therapy can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/20022261?dopt=Abstract" target="%5Fblank"> J Cardiothorac Vasc Anesth 2010 Jun;24(3):487</a></li> <li class="li"> review of noninvasive ventilation for acute respiratory failure can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/23054404?dopt=Abstract" target="%5Fblank"> Intern Emerg Med 2012 Dec;7(6):539</a>, commentary can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/23404259?dopt=Abstract" target="%5Fblank"> Intern Emerg Med 2013 Aug;8(5):453</a></li> <li class="li"> <anchor name="REVIEW-ARTICLES--ANC-1352199889" target-type="anchor"></anchor> review of noninvasive ventilation in cardiogenic pulmonary edema can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/30370282?dopt=Abstract" target="%5Fblank"> Ann Transl Med 2018 Sep;6(18):355</a></li> <li class="li"> review of effects of mechanical ventilation in acute respiratory distress syndrome can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27038480?dopt=Abstract" target="%5Fblank"> Intensive Care Med 2016 May;42(5):739</a></li> <li class="li"> review of capillary leak syndrome can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28318633?dopt=Abstract" target="%5Fblank"> Kidney Int 2017 Jul;92(1):37</a></li> <li class="li">
 review of potential role of cytokine regulation and cystic fibrosis 
transmembrane conductance regulator in pulmonary inflammation and edema 
formation can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28439270?dopt=Abstract" target="%5Fblank"> Front Immunol 2017;8:393</a> <a class="link internal jump-link" href="https://www.frontiersin.org/articles/10.3389/fimmu.2017.00393/full" target="%5Fblank">full-text</a>, commentary can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/29163549?dopt=Abstract" target="%5Fblank"> Front Immunol 2017;8:1490</a></li> <li class="li"> review of lung structure and function can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/20202294?dopt=Abstract" target="%5Fblank"> Int J Tuberc Lung Dis 2010 Apr;14(4):391</a></li> </ul> </section> <section id="sec-MEDLINE-search"> <h3 id="MEDLINE-search">MEDLINE search</h3> <anchor name="MEDLINE-search"></anchor> <ul class="ul"> <li class="li"> to search MEDLINE for (Pulmonary edema) with targeted search (Clinical Queries), click <a class="link internal jump-link" href="https://pubmed.ncbi.nlm.nih.gov/?term=(Pulmonary%20edema)%20AND%20(randomized%20controlled%20trial[Publication%20Type]%20OR%20(randomized[Title/Abstract]%20AND%20controlled[Title/Abstract]%20AND%20trial[Title/Abstract]))" target="%5Fblank">therapy</a>, <a class="link internal jump-link" href="https://pubmed.ncbi.nlm.nih.gov/?term=(Pulmonary%20edema)%20AND%20(specificity[Title/Abstract])" target="%5Fblank">diagnosis</a>, or <a class="link internal jump-link" href="https://pubmed.ncbi.nlm.nih.gov/?term=(Pulmonary%20edema)%20AND%20(prognos*[Title/Abstract]%20OR%20(first[Title/Abstract]%20AND%20episode[Title/Abstract])%20OR%20cohort[Title/Abstract])" target="%5Fblank">prognosis</a></li> </ul> </section> </section> <section id="sec-Patient-Information" collapsible="true" bullettype="arrow"> <h2 id="Patient-Information">Patient Information</h2> <anchor name="Patient-Information"></anchor> <ul class="ul"> <li class="li"> handout from <a class="link internal jump-link" href="https://medical.azureedge.net/pdf/28414.pdf?v=636779865007026858" target="%5Fblank">Patient UK PDF</a></li> </ul> </section> <section id="sec-References" collapsible="true" bullettype="arrow"> <h2 id="References">References</h2> <anchor name="References"></anchor> <section id="sec-General-references-used"> <h3 id="General-references-used">General references used</h3> <anchor name="General-references-used"></anchor> <p> <emph>The
 references listed below are used in this DynaMed topic primarily to 
support background information and for guidance where evidence summaries
 are not felt to be necessary. Most references are incorporated within 
the text along with the evidence summaries.</emph> </p> <ul class="ul"> <li class="li"> <anchor name="GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF6679" target-type="anchor"></anchor>1. Murray JF. Pulmonary edema: pathophysiology and diagnosis. <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/21219673?dopt=Abstract" target="%5Fblank"> Int J Tuberc Lung Dis. 2011 Feb;15(2):155-60</a>, commentary can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/21740685?dopt=Abstract" target="%5Fblank"> Int J Tuberc Lung Dis 2011 Aug;15(8):1135</a></li> <li class="li"> <anchor name="GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3924" target-type="anchor"></anchor>2. Assaad S, Kratzert WB, Shelley B, Friedman MB, Perrino A Jr. Assessment of Pulmonary Edema: Principles and Practice. <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/29174750?dopt=Abstract" target="%5Fblank"> J Cardiothorac Vasc Anesth. 2018 Apr;32(2):901-14</a></li> <li class="li"> <anchor name="GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF3105" target-type="anchor"></anchor>3. Bhattacharya M, Kallet RH, Ware LB, Matthay MA. Negative-Pressure Pulmonary Edema. <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27063348?dopt=Abstract" target="%5Fblank"> Chest. 2016 Oct;150(4):927-33</a></li> <li class="li"> <anchor name="GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF7535" target-type="anchor"></anchor>4. Clark AL, Cleland JG. Causes and treatment of oedema in patients with heart failure. <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/23319101?dopt=Abstract" target="%5Fblank"> Nat Rev Cardiol. 2013 Mar;10(3):156-70</a></li> <li class="li"> <anchor name="GUID-3FEBCA46-E7AB-40A1-BEFB-2149A5AEF32D--GENREF9113" target-type="anchor"></anchor>5. Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/16382065?dopt=Abstract" target="%5Fblank"> N Engl J Med. 2005 Dec 29;353(26):2788-96</a></li> </ul> </section> <section id="sec-Recommendation-grading-systems-used"> <h3 id="Recommendation-grading-systems-used">Recommendation grading systems used</h3> <anchor name="Recommendation-grading-systems-used"></anchor> <ul class="ul"> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--SCCM2017GRADE" target-type="anchor"></anchor> Society of Critical Care Medicine (SCCM) uses Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) <ul class="ul"><li class="li"> strength of recommendation <ul class="ul"><li class="li"> Strong - benefits clearly outweigh risks and burdens (or vice versa) for most, if not all, patients </li><li class="li"> Conditional - benefits and risks closely balanced and/or uncertain </li><li class="li"> Best practice statement - recommendation not conducive to GRADE process </li></ul></li><li class="li"> quality of evidence <ul class="ul"><li class="li">
 High - randomized trials without factors that reduce quality of 
evidence, or well done observational studies with very large magnitude 
of effect </li><li class="li"> Moderate - downgraded randomized trials or upgraded observational studies </li><li class="li"> Low - well done observational studies, or randomized trials with many limitations </li><li class="li">
 Very low - downgraded observational studies (results from individual 
studies at serious or very serious risk of bias, serious inconsistencies
 in results across studies, indirect evidence, sparse or imprecise data,
 or likely publication bias) </li></ul></li><li class="li"> Reference - 
Society of Critical Care Medicine (SCCM) and European Society of 
Intensive Care Medicine (ESICM) guidelines for diagnosis and management 
of critical illness-related corticosteroid insufficiency (CIRCI) in 
critically ill patients (Part I) (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28940011?dopt=Abstract" target="%5Fblank"> Intensive Care Med 2017 Dec;43(12):1751</a>) </li></ul></li> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESICM2017GRADE" target-type="anchor"></anchor> European Society of Intensive Care Medicine (ESICM) grading system for recommendations <ul class="ul"><li class="li"> strength of recommendation <ul class="ul"><li class="li"> Grade 1 (strong) - most people would want recommended course of action and only a small proportion would not </li><li class="li"> Grade 2 (conditional) - majority of people would want recommended course of action, but many would not </li><li class="li">
 Best Practice Statement (BPS) - ungraded strong recommendation in which
 benefit or harm was unequivocal but evidence was difficult to 
categorize by GRADE methodology </li></ul></li><li class="li"> evidence rating <ul class="ul"><li class="li"> Grade A (High) - confidence that true effect lies close to estimate of effect </li><li class="li">
 Grade B (Moderate) - moderately confident in effect estimate; true 
effect likely to be close to estimate of effect, but possible it is 
substantially different </li><li class="li"> Grade C (Low) - limited confidence in effect estimate; true effect may be substantially different from estimate of effect </li><li class="li">
 Grade D (Very low) - very little confidence in effect estimate; true 
effect likely to be substantially different from estimate of effect </li></ul></li><li class="li">
 Reference - ESICM guideline on prevention of acute kidney injury and 
protection of renal function in intensive care unit: 2017 update (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28577069?dopt=Abstract" target="%5Fblank"> Intensive Care Med 2017 Jun;43(6):730</a> <a class="link internal jump-link" href="https://link.springer.com/article/10.1007%2Fs00134-017-4832-y" target="%5Fblank">full-text</a>) </li></ul></li> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCFAHAGRADE" target-type="anchor"></anchor>American College of Cardiology Foundation/American Heart Association (ACCF/AHA) grading system for recommendations <ul class="ul"><li class="li">classifications of recommendations<ul class="ul"><li class="li">Class I - procedure or treatment should be performed or administered</li><li class="li">Class IIa - reasonable to perform procedure or administer treatment, but additional studies with focused objectives needed</li><li class="li">Class
 IIb - procedure or treatment may be considered; additional studies with
 broad objectives needed, additional registry data would be useful</li><li class="li">Class III - procedure or treatment should not be performed or administered because it is not helpful or may be harmful<ul class="ul"><li class="li">Class III ratings may be subclassified as Class III No Benefit or Class III Harm</li></ul></li></ul></li><li class="li">levels of evidence<ul class="ul"><li class="li">Level A - data derived from multiple randomized clinical trials or meta-analyses</li><li class="li">Level B - data derived from single randomized trial or nonrandomized studies</li><li class="li">Level C - only expert opinion, case studies, or standard of care</li></ul></li></ul><ul class="ul"><li class="li"> Reference - ACCF/AHA 2013 guideline on management of heart failure (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/23741058?dopt=Abstract" target="%5Fblank"> Circulation 2013 Oct 15;128(16):e240</a>) </li></ul></li> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCGRADE" target-type="anchor"></anchor> European Society of Cardiology (ESC) grading system for recommendations<ulist id="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--SNIPPET-POINTER-799310150"></ulist></li><li class="li">classes of recommendations<ul class="ul"><li class="li">Class I - evidence and/or general agreement that given treatment or procedure is beneficial, useful, and effective</li><li class="li">Class II - conflicting evidence and/or divergence of opinion about usefulness/efficacy of given treatment or procedure<ul class="ul"><li class="li">Class IIa - weight of evidence/opinion in favor of usefulness/efficacy</li><li class="li">Class IIb - usefulness/efficacy less well established by evidence/opinion</li></ul></li><li class="li">Class
 III - evidence or general agreement that given treatment or procedure 
is not useful/effective, and in some cases may be harmful</li></ul></li><li class="li">levels of evidence<ul class="ul"><li class="li">Level A - data derived from multiple randomized clinical trials or meta-analyses</li><li class="li">Level B - data derived from single randomized clinical trial or large nonrandomized studies</li><li class="li">Level C - consensus of opinion of experts and/or small studies, retrospective studies, registries</li></ul></li></ul><ul class="ul"><li class="li"> Reference - ESC guideline on diagnosis and treatment of acute and chronic heart failure (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27206819?dopt=Abstract" target="%5Fblank"> Eur Heart J 2016 Jul 14;37(27):2129</a> <a class="link internal jump-link" href="https://academic.oup.com/eurheartj/article/37/27/2129/1748921" target="%5Fblank">full-text</a>), correction can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28039335?dopt=Abstract" target="%5Fblank"> Eur Heart J 2018 Mar 7;39(10):860</a>, editorial can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27206818?dopt=Abstract" target="%5Fblank"> Eur Heart J 2016 Jul 14;37(27):2096</a></li></ul> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--SIGNGRADE" target-type="anchor"></anchor> Scottish Intercollegiate Guidelines Network (SIGN) grading system <ul class="ul"><li class="li"> strength of recommendation <ul class="ul"><li class="li">
 Strong - intervention should or should not be used; guideline 
development group confident that for vast majority of people 
intervention will do more harm than good or vice versa </li><li class="li"> Conditional - intervention should be considered <ul class="ul"><li class="li"> guideline development group confident intervention will do more good than harm for most patients </li><li class="li">
 choice of intervention more likely to vary depending on person's values
 and preferences so healthcare professionals should spend more time 
discussing options with patients </li></ul></li><li class="li"> Good Practice Point - recommended best practice based on clinical experience of guideline development group </li></ul></li><li class="li"> levels of evidence <ul class="ul"><li class="li"> Level 1<sc><sups>++</sups></sc> - high-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs) or RCTs with very low risk of bias </li><li class="li"> Level 1<sc><sups>+</sups></sc> - well-conducted meta-analyses, systematic reviews, or RCTs with low risk of bias </li><li class="li"> Level 1<sc><sups>-</sups></sc> - meta-analyses, systematic reviews, or RCTs with high risk of bias </li><li class="li"> Level 2<sc><sups>++</sups></sc><ul class="ul"><li class="li"> high-quality systematic reviews of case-control or cohort studies </li><li class="li">
 high-quality case-control or cohort studies with very low risk of 
confounding or bias and high probability that relationship is causal </li></ul></li><li class="li"> Level 2<sc><sups>+</sups></sc>
 - well-conducted case-control or cohort studies with low risk of 
confounding or bias and moderate probability that relationship is causal
 </li><li class="li"> Level 2<sc><sups>-</sups></sc> - case-control or cohort studies with high risk of confounding or bias and significant risk that relationship not causal </li><li class="li"> Level 3 - nonanalytic studies (such as case reports, case series) </li><li class="li"> Level 4 - expert opinion </li></ul></li><li class="li"> Reference - SIGN national clinical guideline on management of chronic heart failure (<a class="link internal jump-link" href="https://www.sign.ac.uk/assets/sign147.pdf" target="%5Fblank">SIGN 2016 Mar PDF</a>) </li></ul></li> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ATSESICMSCCMGRADE" target-type="anchor"></anchor>
 American Thoracic Society/European Society of Intensive Care 
Medicine/Society of Critical Care Medicine (ATS/ESICM/SCCM) grading 
system <ulist id="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--SNIPPET-POINTER-1587102141"></ulist></li><li class="li">strength of recommendations<ul class="ul"><li class="li">Strong recommendation<ul class="ul"><li class="li">most patients should receive the recommended course of action</li><li class="li">most patients would want the intervention, only a small proportion would not</li></ul></li><li class="li">Conditional/Weak recommendation<ul class="ul"><li class="li">clinicians should be more prepared to help patients make decisions consistent with patient's values</li><li class="li">most patients would want the intervention, but many would not</li></ul></li></ul></li><li class="li">quality of evidence determination and implications/confidence in estimate of effect<ul class="ul"><li class="li">High<ul class="ul"><li class="li">randomized
 trial without limitation in study quality, indirectness, important 
inconsistency, sparse or imprecise data, or high probability of 
publication bias</li><li class="li">further research is very unlikely to change confidence in estimate of effect</li></ul></li><li class="li">Moderate<ul class="ul"><li class="li">downgraded
 randomized trial or upgraded observational study with strong 
association (no plausible confounders), evidence of a dose-response 
gradient, or plausible confounders which would have reduced the effect</li><li class="li">further research is likely to have important impact on confidence in estimate of effect and may change estimate</li></ul></li><li class="li">Low<ul class="ul"><li class="li">well-done observational study with control groups</li><li class="li">further research is very likely to have important impact on confidence in estimate of effect and is likely to change estimate</li></ul></li><li class="li">Very low<ul class="ul"><li class="li">any other evidence (for example, case reports, case series)</li><li class="li">very uncertain about estimate</li></ul></li></ul></li><ul class="ul"><li class="li">
 Reference - ATS/ESICM/SCCM clinical practice guideline on mechanical 
ventilation in adult patients with acute respiratory distress syndrome (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28459336?dopt=Abstract" target="%5Fblank"> Am J Respir Crit Care Med 2017 May 1;195(9):1253</a>), correction can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28569586?dopt=Abstract" target="%5Fblank"> Am J Respir Crit Care Med 2017 Jun 1;195(11):1540</a>, commentary can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28932514?dopt=Abstract" target="%5Fblank"> J Thorac Dis 2017 Aug;9(8):2238</a></li></ul> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--WMSGRADE" target-type="anchor"></anchor> Wilderness Medical Society (WMS) classification for grading evidence and recommendations <ul class="ul"><li class="li"> Grade 1A <ul class="ul"><li class="li"> strong recommendation, high quality evidence </li><li class="li"> benefits clearly outweigh risks and burdens or vice versa </li><li class="li">
 supporting evidence from randomized controlled trials without important
 limitations or overwhelming evidence from observational studies </li></ul></li><li class="li"> Grade 1B <ul class="ul"><li class="li"> strong recommendation, moderate quality evidence </li><li class="li"> benefits clearly outweigh risks and burdens or vice versa </li><li class="li">
 supporting evidence from randomized controlled trials with important 
limitations or exceptionally strong evidence from observational studies </li></ul></li><li class="li"> Grade 1C <ul class="ul"><li class="li"> strong recommendation, low quality or very low quality evidence </li><li class="li"> benefits clearly outweigh risks and burdens or vice versa </li><li class="li"> supporting evidence from observational studies or case series </li></ul></li><li class="li"> Grade 2A <ul class="ul"><li class="li"> weak recommendation, high quality evidence </li><li class="li"> benefits closely balanced with risks and burdens </li><li class="li">
 supporting evidence from randomized controlled trials without important
 limitations or overwhelming evidence from observational studies </li></ul></li><li class="li"> Grade 2B <ul class="ul"><li class="li"> weak recommendation, moderate quality evidence </li><li class="li"> benefits closely balanced with risks and burdens </li><li class="li">
 supporting evidence from randomized controlled trials with important 
limitations or exceptionally strong evidence from observational studies </li></ul></li><li class="li"> Grade 2C <ul class="ul"><li class="li"> weak recommendation, low quality or very low quality evidence </li><li class="li"> uncertainty in estimates of benefits, risks, and burden; benefits, risk, burden may be closely balanced </li><li class="li"> supporting evidence from observational studies or case series </li></ul></li><li class="li"> Reference - WMS consensus guideline on prevention and treatment of acute altitude illness (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/25498261?dopt=Abstract" target="%5Fblank"> Wilderness Environ Med 2014 Dec;25(4 Suppl):S4</a>) </li></ul></li> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACC-AHA-HFSAGRADE" target-type="anchor"></anchor>
 American College of Cardiology/American Heart Association/Heart Failure
 Society of America (ACC/AHA/HFSA) grading system for recommendations <ul class="ul"><li class="li"> classifications of recommendations <ul class="ul"><li class="li"> Class I (Strong) - procedure or treatment should be performed or administered </li><li class="li"> Class IIa (Moderate) - reasonable to perform procedure or administer treatment </li><li class="li">
 Class IIb (Weak) - procedure or treatment may be considered; 
usefulness/effectiveness is unknown, unclear, uncertain, or not well 
established </li><li class="li"> Class III: No Benefit (Moderate) - 
procedure or treatment should not be performed or administered, as it is
 not useful/effective/beneficial </li><li class="li"> Class III: Harm (Strong) - procedure or treatment should not be performed or administered, as it is potentially harmful </li></ul></li><li class="li"> levels of evidence <ul class="ul"><li class="li">
 Level A - high-quality evidence from &gt; 1 randomized controlled trial
 (RCT), meta-analyses of high-quality RCTs, or ≥ 1 RCT corroborated by 
high-quality registry studies </li><li class="li"> Level B-R (Randomized) - moderate-quality evidence from ≥ 1 RCT or meta-analysis of moderate-quality RCTs </li><li class="li">
 Level B-NR (Nonrandomized) - moderate-quality evidence from ≥ 1 
well-designed, well-executed nonrandomized studies, observational 
studies, or registry studies, or meta-analysis of such studies </li><li class="li">
 Level C-LD (Limited Data) - randomized or nonrandomized observational 
or registry studies with limitations of design or execution, 
meta-analyses of such studies, or physiological or mechanistic studies 
in human subjects </li><li class="li"> Level C-EO (Expert Opinion) - consensus of expert opinion based on clinical experience </li></ul></li><li class="li"> References - <ul class="ul"><li class="li"> ACC/AHA/HFSA focused update of 2013 ACCF/AHA guideline on management of heart failure (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28461259?dopt=Abstract" target="%5Fblank"> J Card Fail 2017 Aug;23(8):628</a>, <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28461007?dopt=Abstract" target="%5Fblank"> J Am Coll Cardiol 2017 Aug 8;70(6):776</a> <a class="link internal jump-link" href="http://www.onlinejacc.org/content/70/6/776?%5Fga=2.243160834.1216340351.1517249532-1087571939.1515620869" target="%5Fblank">full-text</a>, or <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28455343?dopt=Abstract" target="%5Fblank"> Circulation 2017 Aug 8;136(6):e137</a>) </li><li class="li">
 ACC/AHA/HFSA focused update on new pharmacological therapy for heart 
failure: update of 2013 ACCF/AHA guideline on management of heart 
failure (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27208050?dopt=Abstract" target="%5Fblank"> Circulation 2016 Sep 27;134(13):e282</a>), correction can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/27672202?dopt=Abstract" target="%5Fblank"> Circulation 2016 Sep 27;134(13):e298</a></li></ul></li></ul></li> <li class="li">
 American Heart Association/American College of Cardiology/Heart Rhythm 
Society (AHA/ACC/HRS) grading system for recommendations <ul class="ul"><li class="li"> classifications of recommendations <ul class="ul"><li class="li"> Class I (Strong) - procedure or treatment should be performed or administered </li><li class="li"> Class IIa (Moderate) - reasonable to perform procedure or administer treatment </li><li class="li">
 Class IIb (Weak) - procedure or treatment may be considered; 
usefulness/effectiveness is unknown, unclear, uncertain, or not well 
established </li><li class="li"> Class III: No Benefit (Moderate) - 
procedure or treatment should not be performed or administered, as it is
 not useful/effective/beneficial </li><li class="li"> Class III: Harm (Strong) - procedure or treatment should not be performed or administered, as it is potentially harmful </li></ul></li><li class="li"> levels of evidence <ul class="ul"><li class="li">
 Level A - high-quality evidence from &gt; 1 randomized controlled trial
 (RCT), meta-analyses of high-quality RCTs, or ≥ 1 RCT corroborated by 
high-quality registry studies </li><li class="li"> Level B-R (Randomized) - moderate-quality evidence from ≥ 1 RCT or meta-analysis of moderate-quality RCTs </li><li class="li">
 Level B-NR (Nonrandomized) - moderate-quality evidence from ≥ 1 
well-designed, well-executed nonrandomized studies, observational 
studies, or registry studies, or meta-analysis of such studies </li><li class="li">
 Level C-LD (Limited Data) - randomized or nonrandomized observational 
or registry studies with limitations of design or execution, 
meta-analyses of such studies, or physiological or mechanistic studies 
in human subjects </li><li class="li"> Level C-EO (Expert Opinion) - consensus of expert opinion based on clinical experience </li></ul></li><li class="li">
 Reference - AHA/ACC/HRS 2017 guideline for evaluation and management of
 patients with ventricular arrhythmias and prevention of sudden cardiac 
death (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/29084733?dopt=Abstract" target="%5Fblank"> Circulation 2018 Sep 25;138(13):e210</a>), correction can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/30354427?dopt=Abstract" target="%5Fblank"> Circulation 2018 Sep 25;138(13):e415</a></li></ul></li> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--NCSGRADE" target-type="anchor"></anchor> Neurocritical Care Society (NCS) grading of recommendations <ul class="ul"><li class="li"> strength of recommendation <ul class="ul"><li class="li"> Strong recommendation </li><li class="li"> Weak recommendation </li></ul></li><li class="li"> quality of evidence <ul class="ul"><li class="li"> High - further research very unlikely to change confidence in estimate of effect </li><li class="li"> Moderate - further research likely to have important impact on confidence in estimate of effect and may change estimate </li><li class="li">
 Low - further research very likely to have important impact on 
confidence in estimate of effect and is likely to change estimate </li><li class="li"> Very low - any estimate of effect is very uncertain </li></ul></li><li class="li">
 Reference - NCS multidisciplinary consensus conference recommendations 
on critical care management of patients following aneurysmal 
subarachnoid hemorrhage (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/21773873?dopt=Abstract" target="%5Fblank"> Neurocrit Care 2011 Sep;15(2):211</a>), commentary can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22108784?dopt=Abstract" target="%5Fblank"> Neurocrit Care 2012 Apr;16(2):343</a></li></ul></li> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHA2017GRADE" target-type="anchor"></anchor>American College of Cardiology/American Heart Association (ACC/AHA) grading system for recommendations 2017 or later<ul class="ul"><li class="li">classifications of recommendations<ul class="ul"><li class="li">Class I - procedure or treatment should be performed or administered</li><li class="li">Class IIa - reasonable to perform procedure or administer treatment, but additional studies with focused objectives needed</li><li class="li">Class
 IIb - procedure or treatment may be considered; additional studies with
 broad objectives needed, additional registry data would be useful</li><li class="li">Class III - procedure or treatment should not be performed or administered because it is not helpful or may be harmful<ul class="ul"><li class="li">Class III ratings may be subclassified as Class III No Benefit or Class III Harm</li></ul></li></ul></li><li class="li">levels of evidence<ul class="ul"><li class="li">Level
 A - high-quality evidence from &gt; 1 randomized controlled trial or 
meta-analysis of high-quality randomized controlled trials</li><li class="li">Level
 B-R - moderate-quality evidence from ≥ 1 randomized controlled trial or
 meta-analysis of moderate-quality randomized controlled trials</li><li class="li">Level
 B-NR - moderate-quality evidence from ≥ 1 well-designed nonrandomized 
trial, observational studies, or registry studies, or meta-analysis of 
such studies</li><li class="li">Level C-LD - randomized or nonrandomized studies with methodological limitations or meta-analyses of such studies</li><li class="li">Level C-EO - consensus of expert opinion based on clinical experience</li></ul></li></ul><ul class="ul"><li class="li"> References<ul class="ul"><li class="li">AHA/ACC 2017 focused guideline update on management of patients with valvular heart disease (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28315732?dopt=Abstract" target="%5Fblank"> J Am Coll Cardiol 2017 Jul 11;70(2):252</a> <a class="link internal jump-link" href="http://www.onlinejacc.org/content/70/2/252" target="%5Fblank">full-text</a> or <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/28298458?dopt=Abstract" target="%5Fblank"> Circulation 2017 Jun 20;135(25):e1159</a>)</li><li class="li">
 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline on 
prevention, detection, evaluation, and management of high blood pressure
 in adults (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/29133356?dopt=Abstract" target="%5Fblank"> Hypertension 2018 Jun;71(6):e13</a> or <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/29146535?dopt=Abstract" target="%5Fblank"> J Am Coll Cardiol 2018 May 15;71(19):e127</a>) </li></ul></li></ul></li> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCAHAGRADE" target-type="anchor"></anchor> American College of Cardiology/American Heart Association (ACC/AHA) grading system for recommendations prior to 2017<ul class="ul"><li class="li">classifications of recommendations<ul class="ul"><li class="li">Class I - procedure or treatment should be performed or administered</li><li class="li">Class IIa - reasonable to perform procedure or administer treatment, but additional studies with focused objectives needed</li><li class="li">Class
 IIb - procedure or treatment may be considered; additional studies with
 broad objectives needed, additional registry data would be useful</li><li class="li">Class III - procedure or treatment should not be performed or administered because it is not helpful or may be harmful<ul class="ul"><li class="li">Class III ratings may be subclassified as Class III No Benefit or Class III Harm</li></ul></li></ul></li><li class="li">levels of evidence<ul class="ul"><li class="li">Level A - data derived from multiple randomized clinical trials or meta-analyses</li><li class="li">Level B - data derived from single randomized trial or nonrandomized studies</li><li class="li">Level C - only expert opinion, case studies, or standard of care</li></ul></li></ul><ul class="ul"><li class="li"> References <ul class="ul"><li class="li"> AHA scientific statement on sexual activity and cardiovascular disease (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22267844?dopt=Abstract" target="%5Fblank"> Circulation 2012 Feb 28;125(8):1058</a> <a class="link internal jump-link" href="http://circ.ahajournals.org/content/125/8/1058.full" target="%5Fblank">full-text</a>) </li><li class="li"> AHA/ACC guideline on management of patients with valvular heart disease (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/24589853?dopt=Abstract" target="%5Fblank"> Circulation 2014 Jun 10;129(23):e521</a> <a class="link internal jump-link" href="http://circ.ahajournals.org/content/early/2014/02/27/CIR.0000000000000031.full.pdf" target="%5Fblank">PDF</a>) </li></ul></li></ul></li> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ESCEACTSGRADE" target-type="anchor"></anchor>European Society of Cardiology/European Association for Cardio-Thoracic Surgery (ESC/EACTS) grading system for recommendations <ul class="ul"><li class="li">classes of recommendations<ul class="ul"><li class="li">Class I - evidence and/or general agreement that given treatment or procedure is beneficial, useful, and effective</li><li class="li">Class II - conflicting evidence and/or divergence of opinion about usefulness/efficacy of given treatment or procedure<ul class="ul"><li class="li">Class IIa - weight of evidence/opinion in favor of usefulness/efficacy</li><li class="li">Class IIb - usefulness/efficacy less well established by evidence/opinion</li></ul></li><li class="li">Class
 III - evidence or general agreement that given treatment or procedure 
is not useful/effective, and in some cases may be harmful</li></ul></li><li class="li">levels of evidence<ul class="ul"><li class="li">Level A - data derived from multiple randomized clinical trials or meta-analyses</li><li class="li">Level B - data derived from single randomized clinical trial or large nonrandomized studies</li><li class="li">Level C - consensus of opinion of experts and/or small studies, retrospective studies, registries</li></ul></li></ul><ul class="ul"><li class="li"> Reference - ESC/EACTS guideline on management of valvular heart disease (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22922415?dopt=Abstract" target="%5Fblank"> Eur Heart J 2012 Oct;33(19):2451</a> <a class="link internal jump-link" href="http://eurheartj.oxfordjournals.org/content/33/19/2451.long" target="%5Fblank">full-text</a> or in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22922698?dopt=Abstract" target="%5Fblank"> Eur J Cardiothorac Surg 2012 Oct;42(4):S1</a>) </li></ul></li> <li class="li"> <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--GRADE2008GRADE" target-type="anchor"></anchor> GRADE system for strength of recommendation <ul class="ul"><li class="li">Strong recommendation - desirable effects of intervention clearly outweigh undesirable effects, or clearly do not </li><li class="li">Weak
 recommendation - trade-offs are less certain, either because of 
low-quality evidence or because evidence suggests that desirable and 
undesirable effects are closely balanced </li><li class="li">Reference - <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/18436948?dopt=Abstract" target="%5Fblank"> BMJ 2008 Apr 26;336(7650):924</a></li></ul></li>  <anchor name="GUID-C4958EF7-A347-4744-A8FF-AF4EADDA8F84--ACCPGRADFEFORPI" target-type="anchor"></anchor> <ul class="ul"> <li class="li"> American College of Chest Physicians (ACCP) grades<ul class="ul"><li class="li">Grade 1 - strong recommendation based on clear risk/benefit balance</li><li class="li">Grade 2 - weak recommendation based on unclear or close risk/benefit balance</li><li class="li">Grade
 A - high-quality evidence based on consistent evidence from randomized 
trials without important limitations or exceptionally strong evidence 
from observational studies</li><li class="li">Grade B - moderate-quality
 evidence based on randomized trials with important limitations 
(inconsistent results, methodologic flaws, indirect or imprecise 
results) or very strong evidence from observational studies</li><li class="li">Grade
 C - low- or very low-quality evidence based on evidence for ≥ 1 
critical outcome from observational studies, case series, or randomized 
trials with serious flaws or indirect evidence</li><li class="li">Reference
 - ACCP evidence-based clinical practice guideline on methodology for 
development of antithrombotic therapy and prevention of thrombosis (<a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/22315256?dopt=Abstract" target="%5Fblank">Chest 2012 Feb;141(2 Suppl):53S</a> <a class="link internal jump-link" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278053/" target="%5Fblank">full-text</a>), commentary can be found in <a class="link internal jump-link" href="http://pubmed.ncbi.nlm.nih.gov/23546508?dopt=Abstract" target="%5Fblank">Chest 2013 Apr;143(4):1190</a></li></ul></li> </ul> </section> <section id="sec-DynaMed-Editorial-Process"> <h3 id="DynaMed-Editorial-Process">DynaMed Editorial Process</h3> <anchor name="DynaMed-Editorial-Process"></anchor> <ul class="ul"> <li class="li">DynaMed topics are created and maintained by the <a class="link internal jump-link" href="http://www.dynamed.com/home/content/editorial-process" target="%5Fblank">DynaMed Editorial Team and Process</a>.</li> <li class="li">All
 editorial team members and reviewers have declared that they have no 
financial or other competing interests related to this topic, unless 
otherwise indicated.</li> <li class="li">DynaMed content includes Practice-Changing Updates, with support from our partners, McMaster University and F1000.</li> </ul> </section> <section id="sec-Special-acknowledgements"> <h3 id="Special-acknowledgements">Special acknowledgements</h3> <anchor name="Special-acknowledgements"></anchor> <!--SEC NO TITLE--> <ul class="ul"> <li class="li">Constantine Manthous, MD (Staff Intensivist, Lawrence and Memorial Hospital &amp; IPC; Connecticut, United States)</li> <li class="li">Dr. Manthous declares no relevant financial conflicts of interest.</li> </ul> <ulist id="GUID-065D462D-96B2-4DA1-A6C6-4CF2BF9C490A--SNIPPET-POINTER-929960894"> <li class="li">Terence
 K. Trow, MD, FACP, FCCP (Senior Deputy Editor of Pulmonary, Critical 
Care, and Sleep Medicine; Ex-Director of the Yale Pulmonary Vascular 
Disease Program, Associate Clinical Professor of Medicine, Yale 
University School of Medicine; Connecticut, United States)</li> <li class="li">Dr. Trow declares no relevant financial conflicts of interest.</li>  <ul class="ul"> <li class="li">DynaMed
 topics are written and edited through the collaborative efforts of the 
above individuals. Deputy Editors, Section Editors, and Topic Editors 
are active in clinical or academic medical practice. Recommendations 
Editors are actively involved in development and/or evaluation of 
guidelines.</li> </ul> <ul class="ul"> <li class="li"> <bold>Editorial Team role definitions</bold> <ephtml><div class="TableModal_modalContent" data-auto="table-details"><table class="table" frame="border" rules="all" summary="" id="ID0EQOBI" cellspacing="0" cellpadding="4" border="1"><colgroup><col style="width:100%"></colgroup><tbody><tr class="row"><td class="entry cellrowborder">Topic
 Editors define the scope and focus of each topic by formulating a set 
of clinical questions and suggesting important guidelines, clinical 
trials, and other data to be addressed within each topic. Topic Editors 
also serve as consultants for the DynaMed internal Editorial Team during
 the writing and editing process, and review the final topic drafts 
prior to publication.</td></tr><tr class="row"><td class="entry cellrowborder">Section
 Editors have similar responsibilities to Topic Editors but have a 
broader role that includes the review of multiple topics, oversight of 
Topic Editors, and systematic surveillance of the medical literature.</td></tr><tr class="row"><td class="entry cellrowborder">Deputy
 Editors are employees of DynaMed and oversee DynaMed internal 
publishing groups. Each is responsible for all content published within 
that group, including supervising topic development at all stages of the
 writing and editing process, final review of all topics prior to 
publication, and direction of an internal team.</td></tr></tbody></table></div></ephtml> </li> </ul> </ulist></section> <section id="sec-How-to-cite"> <h3 id="How-to-cite">How to cite</h3> <anchor name="How-to-cite"></anchor> <p>National Library of Medicine, or "Vancouver style" (International Committee of Medical Journal Editors):</p> <ul class="ul"> <li class="li">DynaMed
 [Internet]. Ipswich (MA): EBSCO Information Services. 1995 - . Record 
No. T922139, PPulmonary Edema - Approach to the Patient; [updated 2018 
Dec 05, cited <bold>place cited date here</bold>]. Available from https://www.dynamed.com/topics/dmp~AN~T922139. Registration and login required.</li> </ul> </section> </section> <hidden type="epref"> <epref> <eplink type="pubmed" ui="26230356"> <epft an="109475544" db="a9h" format="t p"></epft> <epft an="109475544" db="cxh" format="t p"></epft> <epft an="26230356" db="mdc" format="p"></epft> </eplink> <eplink type="pubmed" ui="28318633"></eplink> <eplink type="pubmed" ui="28439270"></eplink> <eplink type="pubmed" ui="22611136"></eplink> <eplink type="pubmed" ui="17353535"> <epft an="17353535" db="mnh" format="p"></epft> <epft an="17353535" db="mdc" format="p"></epft> </eplink> <eplink type="pubmed" ui="27206819"></eplink> <eplink type="pubmed" ui="25340219"></eplink> <eplink type="pubmed" ui="20511258"></eplink> <eplink type="pubmed" ui="28577069"> <epft an="28577069" db="mnh" format="p"></epft> <epft an="123518791" db="cxh" format="p"></epft> <epft an="28577069" db="mdc" format="p"></epft> </eplink> <eplink type="pubmed" ui="23741058"></eplink> <eplink type="pubmed" ui="28459336"></eplink> <eplink type="pubmed" ui="29959871"> <epft an="CD009567" db="chh" format="t c p"></epft> </eplink> <eplink type="pubmed" ui="23772167"></eplink> <eplink type="pubmed" ui="22396565"></eplink> <eplink type="pubmed" ui="22948592"></eplink> <eplink type="pubmed" ui="26469827"></eplink> <eplink type="pubmed" ui="19188546"></eplink> <eplink type="pubmed" ui="28569586"></eplink> <eplink type="pubmed" ui="28932514"> <epft an="125379985" db="cxh" format="p"></epft> </eplink> <eplink type="pubmed" ui="28461259"></eplink> <eplink type="pubmed" ui="28461007"></eplink> <eplink type="pubmed" ui="28455343"></eplink> <eplink type="pubmed" ui="27208050"></eplink> <eplink type="pubmed" ui="27672202"></eplink> <eplink type="pubmed" ui="22315261"></eplink> <eplink type="pubmed" ui="22796860"></eplink> <eplink type="pubmed" ui="22751760"> <epft an="22751760" db="mnh" format="p"></epft> <epft an="22751760" db="mdc" format="p"></epft> </eplink> <eplink type="pubmed" ui="25498261"></eplink> <eplink type="pubmed" ui="25392034"> <epft an="25392034" db="mnh" format="p"></epft> <epft an="99567093" db="cxh" format="p"></epft> <epft an="25392034" db="mdc" format="p"></epft> </eplink> <eplink type="pubmed" ui="28039335"></eplink> <eplink type="pubmed" ui="22858653"></eplink> <eplink type="pubmed" ui="20721452"></eplink> <eplink type="pubmed" ui="21219673"></eplink> <eplink type="pubmed" ui="21740685"></eplink> <eplink type="pubmed" ui="29174750"></eplink> <eplink type="pubmed" ui="27490597"></eplink> <eplink type="pubmed" ui="27063348"></eplink> <eplink type="pubmed" ui="20413250"></eplink> <eplink type="pubmed" ui="19917337"></eplink> <eplink type="pubmed" ui="28238713"></eplink> <eplink type="pubmed" ui="16382065"></eplink> <eplink type="pubmed" ui="23319101"></eplink> <eplink type="pubmed" ui="20417341"></eplink> <eplink type="pubmed" ui="18973635"></eplink> <eplink type="pubmed" ui="18973633"></eplink> <eplink type="pubmed" ui="19422415"></eplink> <eplink type="pubmed" ui="23835455"></eplink> <eplink type="pubmed" ui="28465120"></eplink> <eplink type="pubmed" ui="20022261"></eplink> <eplink type="pubmed" ui="23054404"> <epft an="83370965" db="cxh" format="p"></epft> <epft an="23054404" db="mdc" format="p"></epft> </eplink> <eplink type="pubmed" ui="23404259"> <epft an="89093780" db="cxh" format="p"></epft> <epft an="23404259" db="mdc" format="p"></epft> </eplink> <eplink type="pubmed" ui="30370282"></eplink> <eplink type="pubmed" ui="27038480"> <epft an="27038480" db="mnh" format="p"></epft> <epft an="114512535" db="cxh" format="p"></epft> <epft an="27038480" db="mdc" format="p"></epft> </eplink> <eplink type="pubmed" ui="29163549"></eplink> <eplink type="pubmed" ui="20202294"></eplink> <eplink type="pubmed" ui="28940011"></eplink> <eplink type="pubmed" ui="27206818"></eplink> <eplink type="pubmed" ui="29084733"></eplink> <eplink type="pubmed" ui="30354427"></eplink> <eplink type="pubmed" ui="21773873"></eplink> <eplink type="pubmed" ui="22108784"></eplink> <eplink type="pubmed" ui="22315256"></eplink> <eplink type="pubmed" ui="23546508"></eplink> </epref> </hidden></ulist></div></div></div></div></div></div></body></html>